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ABSTRACT
In the complex relationships of mammalian viruses with their hosts, it is currently
unclear as to what role RNA silencing pathways play during the course of infection. RNA
silencing-based immunity is the cornerstone of plant and invertebrate defense against
viral pathogens, and examples of host defense mechanisms and numerous viral counter-
defense mechanisms exist.   Recent studies indicate that RNA silencing might also play
an active role in the context of a mammalian virus infection.  We show here that a
mammalian virus, human adenovirus, interacts with RNA silencing pathways during
infection, as the virus produces microRNAs (miRNAs) and regulates the expression of
Dicer, a key component of RNA silencing mechanisms.
  Our work demonstrates that adenovirus encodes two miRNAs within the loci of
the virus-associated RNA I (VA RNA I).  We find that one of these miRNAs, miR-VA
“g”, enters into a functional, Argonaute-2 (Ago-2)-containing silencing complex during
infection.  Currently, the cellular or viral target genes for these miRNAs remain
unidentified.  Inhibition of the function of the miRNAs during infection did not affect
viral growth in a highly cytopathic cell culture model. However, studies from other
viruses implicate viral miRNAs in the establishment of latent or chronic infections.
Additionally, we find that adenovirus infection leads to the reduced expression of
Dicer.  This downregulation does not appear to be dependent on the presence of VA RNA
or its associated miRNAs.  Rather, Dicer levels appear to inversely correlate with the
level of viral replication, indicating that another viral gene product is responsible for this
v
activity.  Misregulation of Dicer expression does not appear to influence viral growth in a
cell culture model of infection, and also does not lead to gross changes in the pool of
cellular miRNAs.  Taken together, our results demonstrate that RNA silencing pathways
are active participants in the process of infection with human adenovirus.  The production
of viral miRNAs and the regulation of cellular Dicer levels during infection implicate
RNA silencing mechanisms in both viral fitness as well as potential host defense
strategies.
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CHAPTER I:
INTRODUCTION
1
A. Overview of host-virus relationship
Infection of host organisms by viruses is an active and constantly evolving
interaction.  Organisms go to great lengths in their attempts to stay free of pathogens, and
examples of host defense mechanisms reside in species as diverse as mammals, plants,
flies, and fungi.  Mammalian host cells employ a dizzying array of mechanisms to
combat viral infection, even going so far as to direct the equivalent of cellular euthanasia,
or apoptosis, of infected cells for the overall benefit of the organism.  As obligate
parasites, viruses are dependent upon infection of host organisms to maintain their
survival.  Therefore, the process of viral infection is a delicate balance involving the
ability of the virus to replicate efficiently in the face of host defense mechanisms.  The
virus not only needs to evade host defense mechanisms, but must also subjugate host cell
machinery for its own use to achieve viral replication or to maintain a stable, latent state
within cells.  The continual interplay of invading viruses with host cells drives co-
evolution of these parties.  Similarly, our understanding of the viral and host factors
dictating this relationship continues to evolve.
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B. Mammalian immune defense against viruses
Kinetics of the host immune response to virus
The immune response of mammals is composed of an early, non-specific innate
response, followed by a specific, acquired response to the virus. While initially believed
to be separate and distinct responses to pathogens, numerous studies now indicate that
these responses are entwined to produce a robust, integrated immune response for the
host (90, 124).  When virus succeeds in entering the host and infecting cells, it triggers a
variety of “danger” signals, which serve to broadcast the presence of an infection to the
host (123).  Typical primary responders in this process are dendritic cells (DCs) (69,
191).  Viral recognition by DCs or other innate immune cells via direct infection or virus-
induced death of neighboring cells leads to the local production of chemokines and
cytokines, triggering an inflammatory and adaptive immune response (69, 76).  Of these
cytokines, interferons (IFNs) are the key mediators in the induction of the innate response
as well as the subsequent adaptive response (45, 76, 90).  Type I and II interferons
function to elicit numerous cellular immune factors which give rise to a general antiviral
state at both the cellular and organismal level. In addition to upregulating expression of
manifold cellular effector molecules, interferons also induce DCs to mature as antigen
presenting cells for recognition by lymphocytes, and induce the expression of
chemokines which direct monocytes and lymphocytes to the site of infection (69, 76).
Recognition of viral antigen by specific T or B cells leads to rapid expansion of this
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subset of cells and the production of virus-specific, cytotoxic helper T cells and antibody
producing B cells, the cellular hallmarks of the acquired response (69, 191).  Typically,
the innate response begins with viral recognition and maintains in various forms
throughout the infection, while the virus-specific cytotoxic T lymphocytes (CTL)
responses normally peak at 7-10 days after infection, followed by the appearance of
antibody-producing B cells (192).
Virus recognition by the innate response: dsRNA
Activation of the innate response by virus typically occurs when cells involved in
the innate response, such as DCs, are directly infected or exposed to viral components
through the lysis of nearby infected cells (191). The most common molecular indicator of
viral infection is the presence of double-stranded RNA (dsRNA).  For most viruses,
spurious dsRNA species arise as a consequence of viral replication (68).  Mammalian
cells express a variety of factors that recognize dsRNA as a foreign, pathogenic material.
Until very recently, it was believed that the initial cellular responders to dsRNA were
protein kinase R (PKR), which shuts off host translation in response to dsRNA, and
2´-5´oligoadenylate synthetase (2-5A), which activates the endoribonuclease RNase L.
Expression of both of these molecules is greatly induced by type-1 interferons and they
are both active participants in recognition of dsRNA (45, 132).  However, several studies
of mice with genetic deletion of the PKR or RNase L genes indicated that these
molecules were important as IFN-induced effectors, but did not play a significant role in
4
the initial induction of type-1 IFN (167, 195, 210).  These experiments indicated that
other dsRNA sensors were involved in the initial induction of IFN in virus-infected cells.
Pattern recognition receptors as primary dsRNA sensors
Recent studies have demonstrated that initial recognition of dsRNA occurs
primarily through pattern recognition receptors (PRRs).  These receptor molecules are
expressed in a wide variety of cells involved in the innate immune response, and they
function to detect specific conserved motifs or moieties common to pathogens, known as
pathogen-associated molecular patterns (PAMPs) (76, 132, 148).
The best-studied PRRs are the Toll-like receptors (TLRs), a family of eleven
receptor molecules that recognize PAMPs from a broad range of pathogens including
viruses, bacteria, fungi, and protozoa (1, 76, 132).  The various TLRs are expressed on
different cell types as well as differing cellular compartments.  Individual TLRs
recognize specific PAMPs, such as bacterial lipopolysaccharide (TLR4), non-methylated
CpG DNA (TLR9), single-strand RNA (TLR7, TLR8), and double-stranded RNA
(TLR3) (1, 2).  While most TLRs reside on the plasma membrane, the four family
members which have been associated with viral recognition (TLR3, TLR7, TLR8, and
TLR9) are located in intracellular compartments, such as endosomes.  Activation of all of
these TLRs leads to a signaling cascade culminating in the induction of cytokines,
including type-1 IFN (Fig. 1.1) (76, 132).
5
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In addition to TLRs, several other dsRNA-sensing PRRS have recently been
identified.  The cellular RNA helicases, retinoic acid inducible gene-I (RIG-I) and the
melanoma differentiation-associated gene (MDA5/Helicard), also appear to act as
intracellular PRRs.  RIG-I contains two caspase recruitment domain (CARD)-like
domains and a RNA helicase domain.  The helicase domain recognizes viral dsRNA and
the CARD domains are responsible for triggering a signaling cascade leading to
interferon regulatory factor 3 (IRF3) and NK-κB (Fig.1.1) (132, 201, 207).  Over-
expression of RIG-I was able to block infection from several viruses, and studies using
fibroblasts and DCs from RIG-I-/- mice demonstrated that these cells were almost
completely deficient in their ability to produce type-1 IFN and inflammatory cytokines in
response to viral infections (75, 201).  MDA5 is closely related to RIG-I structurally and
functionally.  This molecule also contains an RNA helicase domain and two CARD-like
domains that are critical for IRF and NK-κB activation.  Over-expression and knockdown
studies of this gene produced similar results as seen with RIG-I: over-expression of
MDA5 induced a more robust type-1 IFN response to virus, and MDA5 knockdowns
prevented appropriate IFN responses in the context of viral infection (5, 74, 200).
The study of PRRs is a relatively young field, and new candidate dsRNA-sensors
are still being characterized (76, 132).  The identification of PRRs helps shed light on the
former immunological grey area of how a host can mount efficient innate responses to
multiple and varied pathogens. TLR3, RIG-I, and MDA5 compose a network of innate
dsRNA sensors that can cover a broad range of cells.  It appears that these PRRs work in
separate cell types as well as separate cellular compartments.  Analysis of RIG-I-/- mice
7
suggests that TLRs are activated from endosomes of plasmacytoid dendritic cells (pDCs),
while RIG-I appears to operate in the cytoplasm of DCs and fibroblasts (75).  It is likely
that these PRRs and potentially other yet to be identified dsRNA-sensing PRRs act as
immune sentinels for identifying viral infection.  Together with PKR and 2-5A, these
molecules underscore the importance of dsRNA recognition in the early stages of the
immune response to virus.  Identification of dsRNA by these molecules leads to the
production of an antiviral state, where high levels of type-1 IFN production sound the
alarm for the host and kickstart the acquired phase of the immune response (76, 90).
C. Viral inhibition of cellular dsRNA-sensing molecules
Inhibitors of PRR signaling
A general assumption in the study of virus/host interactions is that for every
example of host-mediated immune defense against viruses, corresponding examples of
viral inhibitors to this defense pathway exist.  As initial responders to dsRNA introduced
by viral infection, the PRRs are not an exception to this assumption.  Several viral
inhibitors which disrupt the signaling molecules downstream of PRRs have been
identified (76, 132).  The vaccinia virus A46R, hepatitis C virus (HCV) NS3-4A protein,
paramyxovirus V proteins, and Kaposi’s sarcoma-associated herpesvirus (KSHV) RTA
protein all target components of the signaling cascade involved in induction of type-1
IFN production from dsRNA sensors (5, 43, 102, 170, 172, 202).
8
Inhibitors of 2-5A and PKR
The IFN-induced dsRNA response factors 2-5A and PKR represent some of the
best-studied examples of cellular targets for viral inhibition of the host immune response.
A wide array of inhibitors encoded by numerous viruses focus on inactivation of these
proteins, with a particular emphasis on PKR (45, 185).  Inhibition of these proteins is
essential for most infections, since downstream consequences of their activation include
increased IFN production, destruction of mRNA transcripts, and host protein synthesis
shutoff (185).  For most viruses, transcription and translation of viral factors requires host
cell components.  The indiscriminate targeting of mRNAs, both viral and cellular, for
degradation, and the ablation of global protein synthesis demonstrate a general anti-viral
state in which the cell subjugates all activities in an effort to prevent dissemination of
virus and to signal the presence of a viral pathogen in the host.
Activation of the 2-5A pathway occurs when 2-5A synthetase molecules come
into contact with dsRNA.  This interaction results in the formation of oligomers of ATP
residues with a 2´-5´linkage (77, 209).  These 2-5A molecules subsequently activate the
cellular RNase L protein, which directs cleavage of mRNA at specific sequences (3´of
UpNp) (41).  The 2-5A pathway has been shown to influence replication of several
viruses, including vaccinia virus, encephalomyocarditis virus (EMC), and reovirus (136,
151, 194).  Correspondingly, several viral-encoded inhibitors of the 2-5A pathway have
been identified.  Not surprisingly, the highly immunomodulatory vaccinia virus interferes
9
with the pathway, as the E3L protein was shown to inhibit 2-5A synthetase function in in
vitro assays (152). Additionally, herpes simplex viruses encode 2-5A derivatives which
act as antagonists of 2-5A, and EMC virus and HIV have been demonstrated to block the
2-5A/RNase L pathway by inducing the expression of a cellular inhibitor of RNase L
(119, 120).
The powerful and robust cellular PKR response results in the inhibition of cellular
translation in response to dsRNA.  Expressed at low levels in mammalian tissues, PKR
becomes activated rapidly after binding dsRNA through its double-strand RNA binding
domains (dsRBD) (10, 45, 51).  Activation of the kinase function of PKR requires
dimerization and subsequent intermolecular autophosphorylation events (141, 153).
Activated PKR then phosphorylates the cellular translation factor, eukaryotic initiation
factor 2 (eIF-2), blocking its normal role in translation initiation (28).  The eIF-2
initiation factor is made up of α, β, and γ subunits.  Under normal circumstances, the eIF-
2 forms a ternary complex, along with GTP and the initiator methionyl tRNA.  After
initiation of translation is complete, eIF-2, now bound to GDP, is released from the
ribosome.  Another initiation factor, eIF-2b, acts as a guanosine exchange factor (GEF),
catalyzing the exchange of a GTP molecule for the bound GDP on eIF-2, so that the
complex can be recycled and start another round of initiation for polypeptide synthesis.
However, PKR-induced phosphorylation of the α subunit of eIF-2 prevents the ability of
eIF-2b to recycle guanosines, resulting in the “trapping” of the eIF-2 initiation factor in
an inactive conformation (Fig. 1.2).  When sufficient eIF-2 becomes trapped, translation
of both cellular and viral mRNAs is halted (45, 99, 122, 156).
10
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While the 2-5A pathway has been formally demonstrated to regulate replication
of only a select list of viruses, the PKR response appears to be of paramount importance
to the replication of many viruses, based on the number of viral inhibitors directed at this
pathway. Viral inhibition of the pathway can be found for every stage of the PKR
response, from binding of dsRNA to the activation of eIF-2α  phosphatase (45, 185).
Examples include viral proteins, as well as structured viral RNAs that bind and inhibit
PKR, such as the adenovirus VA RNAs, Epstein-Barr Virus EBERs, and human
immunodeficiency virus TAR RNA.  Of these inhibitors, the VA RNAs are the best
studied; in fact, the initial studies of VA RNA were the first to provide evidence of viral
subversion of the PKR response.
D. Adenoviruses and the VA RNA genes
Identification of adenovirus and associated diseases
The initial identification of adenovirus occurred in 1953 when a previously
unknown virus was isolated from primary cells derived from human adenoid tissue (155).
Presently, the Adenoviridae family is composed of two genera: the Aviadenovirus, which
infect birds, and the Mastadenovirus, which infect a variety of mammals, including
humans, simians, pigs, and rodents (165).  There are currently 49 distinct serotypes of
adenovirus (divided into 6 subgroups (A-F)) that infect humans (Centers for Disease
Control Website, 2/07). Adenovirus are classified as DNA tumor viruses based on the
12
ability of the virus to transform cultured cells, as well as the ability of particular strains of
the virus to induce tumors in rodents (155, 175).  Infection occurs primarily through the
respiratory tract leading to respiratory disease, but the virus can also infect the
conjunctiva, giving rise to conjunctivitis (“pink eye”), and adenovirus infection has also
been associated with infantile gastroenteritis (165).  While the virus is most commonly
associated with acute infections, the virus is also able to establish a persistent infection,
as virus has been isolated from lymphocytes in addition to adenoid and tonsilar tissue
(48, 87, 181).
General features of adenovirus
Adenovirus virions are icosahedral, non-enveloped particles that infect cells
though an interaction of the viral fiber protein and a membrane-bound coxsackievirus and
adenovirus receptor (CAR) (13, 165).  The genome of the virus is composed of linear,
double-strand DNA (dsDNA) and the genome size is ~36 kilobases (kb) (165).
Adenovirus viral transcripts are produced from both strands of the genome and
the virus uses a temporal mode of gene expression, with early gene products regulating
expression of numerous host genes to establish an environment conducive to viral
replication, and late gene products (L1-L5) encoding the structural components of the
virus (165).  The early gene products E1a and E1b were identified as the viral factors
responsible for transformation of cultured cells.  These proteins disrupt the activities of
numerous cell cycle regulators, simultaneously activating transcription of viral genes,
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while promoting cell cycle progression.  Like the other DNA tumor viruses, adenovirus
achieves cellular transformation by inactivating the cellular p53 and retinoblastoma (RB)
proteins.  The cultured human 293 cell line is the result of cellular immortalization and
transformation by E1a and E1b.  The other major early transcriptional units of adenovirus
are the E2, E3, and E4 genes, and the virus-associated RNAs (VA RNAs) (165).  The E2
gene encodes proteins involved in replication of the viral genome, while the E3 and E4
gene products, like the E1 gene products, regulate a wide range of cellular proteins to
promote an environment for adenovirus replication.  The activities of the E3- and E4-
encoded proteins are broad, as E3 gene products have been reported to alter numerous
immune and inflammatory mediators and the E4 gene products are reported to modulate
transcription, the cell cycle, cell signaling, DNA repair, and immune mediators (39, 165,
190).  Adenovirus vectors are now commonly used for transduction of transgenes into
cultured cells and laboratory animals in laboratory settings and their clinical application
for gene therapy is an active area of research.  Importantly, these viral vectors contain
deletions of the E1 and E3 genes to reduce the oncogenic and anti-immunogenic qualities
of the vectors (47).
Historically, adenoviruses have been an extremely fruitful area of research,
producing several groundbreaking studies that affected multiple biological fields.  The
most famous of these discoveries was the identification of the processing of mRNA
molecules or “splicing” (9, 14).  Additionally, investigation of the E1a function led to the
discovery of the E2F family of transcription factors.  The first E2F protein was so named
because the first promoter it was found to bind was the adenovirus E2 promoter (84).
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Finally, experiments performed to ascertain the function of the VA RNA genes of
adenovirus demonstrated the importance of the cellular PKR response to viral infection
(83, 173).
Virus-associated RNAs (VA RNAs) of adenovirus
VA RNAs are a class of small RNAs (~160 nucleotides) produced at very high
levels during adenovirus infection (Fig. 1.3). These RNAs are transcribed by RNA
polymerase III and contain neither a 5´cap structure nor a 3´poly-adenylate tail.  Rather,
these highly structured molecules accumulate to levels as high as 108 molecules (VA
RNA I) and 107 molecules (VA RNA II) in infected cells (168).  The RNAs contain
internal Box A and Box B promoter sites, characteristic of RNA polymerase III
transcripts (25, 42, 55).  Mammalian adenoviruses of groups C, D, E, and most of B,
encode two related VA RNA genes, VA RNA I and VA RNA II.  Viruses of groups A, F,
SA7, and several from group B, encode only a single VA species.  Of the 49 known
human serotypes, only 9 encode a single VA RNA gene, and in these instances, the single
VA gene is of the VA RNA I family (114).
Extensive phylogenetic analysis of the VA RNA species from the various
adenovirus groups has been performed.  The genomic location of the VA RNA genes in
relation to neighboring genes reflects the compact, highly efficient nature of viral
genomes, as the VA RNA loci very closely abut protein-coding sequences.  Only ~30
nucleotides separate the 5´end of VA RNA I from an upstream splice site for the pTP
15
Fig. 1.3: Predicted structure of VA RNA I.
Putative structure of VA RNA for Group C adenovirus, as determined from nuclease 
sensitivity assays, site directed mutagenesis, and MFOLD RNA structure prediction 
(Zuker analysis).  Figure reproduced from Ma and Mathews, J. Virol., 70, p. 5083-5099.
Apical Stem
Terminal Stem
Central Domain
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gene.  Similarly, there are only ~20 nucleotides downstream from the 3´ end of VA RNA
II and a splice site of the 52,55K L1 protein (114).  Essentially, only the ~100 nucleotides
separating the VA RNA I gene from the VA RNA II gene are non-coding in this portion
of the genome.
Genetic studies of the VA RNA molecules led to the seminal findings of the
molecule’s role in blocking the host PKR response.  Viruses containing deletions of VA
RNA II grew to the same level as wild type virus, while VA RNA I-deleted virus (dl331)
were found to grow poorly in relation to wild type virus (~10 fold reduced virus
production), and viruses containing deletions of both VA RNA genes grew even more
poorly (~60 fold reduced).  This result suggested that VA RNA II was able to partially
substitute for VA RNA I in the dl331 single mutant virus (17, 173).  Further studies of
the dl331 provided evidence that the cell growth defect was caused by inefficient protein
synthesis at late times of infection, and this defect was traced to defective initiation of
translation (150, 173).  Phosphorylated forms of the translation initiation factor eIF2α
were found in the dl331-infected cells, implying the activity of what was at the time
known as eIF2 kinase, or dsRNA-activated inhibitor (DAI) (150, 159).  This DAI kinase
is now known as PKR.  Additionally, it was shown that extracts from dl331-infected cells
could be rescued for protein synthesis when eIF2 was added to the extract, and
experiments in cells expressing low levels of PKR demonstrated that the dl331 virus
grew similar to the wild type virus (139, 150, 159).
The implication of PKR as a target for VA RNA regulation led to the logical
assumption that the structured VA RNA molecule likely acted as a competitive inhibitor
17
of PKR.  This would prevent the recognition by PKR of virus-derived dsRNA that is
produced during infection (116).  A series of careful mutagenesis experiments have been
performed on VA RNA I in order to determine the functional domains of the molecule
and potential interactions with PKR (44, 113, 128).  These studies identified the apical
stem region of the VA RNA molecule as crucial to the binding of PKR, and the central
domain as the region responsible for PKR inactivation (Fig. 1.3).  Interestingly,
phylogenetic analysis of the VA RNA molecules indicates that the apical stem and
central domain are less conserved than the terminal stem of the molecule, which is not
implicated in PKR interaction (114). However, the high conservation of sequence in the
terminal stem may simply be attributed to the presence of the Box A internal promoter
for RNA polymerase III (25, 42, 55).
Taken together, these results demonstrated that the high levels of VA RNA
produced in infected cells act as competitive inhibitors of PKR, preventing its binding to
virally-derived dsRNA and subsequent activation (Fig. 1.4).  These studies were the first
to define the important role for PKR in the virus/host relationship.
Recently, VA RNAs were shown to utilize the nuclear export factor, Exportin-5,
to transit from the nucleus to the cytoplasm.  Interestingly, this same export factor was
found to export endogenous, structured dsRNA molecules called pre-microRNAs (pre-
miRNAs) (59, 112, 206).  These molecules are involved in an endogenous gene silencing
pathway based on dsRNA substrates.  Numerous examples of related gene silencing
pathways have been described in a variety of organisms, and some of these have been
shown to act as immune defense systems against pathogens (127).
18
F
ig
. 1
.4
: 
A
de
no
vi
ru
s 
V
A
 R
N
A
 b
lo
ck
s 
P
K
R
 a
ct
iv
at
io
n.
A
de
no
vi
ru
s 
in
fe
ct
io
n 
re
su
lts
 i
n 
bi
-d
ir
ec
tio
na
l 
tr
an
sc
ri
pt
io
n 
of
 g
en
om
e 
le
ad
in
g 
to
 p
ro
du
ct
io
n 
of
 d
sR
N
A
 s
pe
ci
es
.  
H
ig
h 
le
ve
ls
 o
f 
V
A
 R
N
A
 b
in
d 
an
d 
se
qu
es
te
r 
PK
R
, p
re
ve
nt
in
g 
its
 a
ct
iv
at
io
n.
  V
ir
al
 a
nd
 h
os
t m
R
N
A
 a
re
 t
ra
ns
la
te
d 
by
 c
el
lu
la
r 
tr
an
sl
at
io
na
l m
ac
hi
ne
ry
.
C
A
R
*
* PK
R
P
K
R
vi
ra
l d
sR
N
A
 v
ira
l
R
N
A
s 
E
xp
5
P
K
R
P
K
R
P
K
R
P
K
R
 v
ira
l
R
N
A
s 
VA
 R
N
A
 
19
E. RNA silencing
The discovery of RNA silencing pathways
In the early 1990s, plant researchers attempting to engineer more attractive
flowers stumbled upon a puzzling result.  By introducing a transgene to increase
production of the chalcone synthetase gene responsible for pigment production in
petunias, the researchers expected to generate flowers with greater purple hues.
However, the plants that they generated displayed flowers with variegated coloring or
sometimes completely lacking in pigment (135).  Not long after these studies, a genetic
screen devised to find mutants in developmental timing of worm larvae produced a loss-
of-function gene that did not encode protein.  Mysteriously, the gene encoded a short
hairpin RNA molecule with antisense complementarity to a heterochronic gene (93).  Just
several years later, scientists attempting to use antisense technology to regulate gene
expression in C. elegans were surprised to find that the controls for the experiments,
sense RNA molecules, sometimes produced similar effects to the antisense RNAs (56,
131).  Unbeknownst to them initially, all of these researchers had stumbled upon related
mechanisms of RNA-based silencing.
The mechanisms and pathways of RNA silencing began to come into focus when
Andrew Fire and Craig Mello solved the conundrum of the aforementioned antisense
experiments.  They proposed that both the sense and antisense RNA preparations in such
20
experiments were not completely pure populations of RNA, and that dsRNA
contamination was likely present in small quantities in the RNA preparation (131).  When
intentionally-generated, specific dsRNA preparations were used in similar studies, highly
efficient and specific silencing of the target gene was achieved.  Additionally, silencing
initiated in the worms could be passed through the germline to their progeny (40).  This
Nobel Prize-winning experiment describing RNA interference (RNAi) brought the study
of dsRNA to the forefront of biology and led to the identification of a wide array of RNA
silencing mechanisms that are still being uncovered at a rapid pace.
Examples of RNA silencing now include a diverse group of organisms that
includes yeast, fungi, worms, flies, plants, and mammals. The common feature in all of
these pathways is the recognition of a dsRNA substrate or “trigger”.  Similar to the potent
non-specific immune response to dsRNA in mammalian cells, a multitude of other
organisms had now been found to rely on host mechanisms to detect and respond to long
stretches of dsRNA as foreign, pathogenic material.  Traditionally, the term RNAi is used
to refer to the silencing pathways triggered by long dsRNA molecules, which leads to
specific gene silencing.  Examples of this occur in related, but distinct pathways in
species such as worms, flies, and plants.  Experiments in plants and fly extract
demonstrated that in these organisms, the long dsRNA is processed into short, ~21-26
nucleotide dsRNAs, or short, interfering RNAs (siRNAs).  These siRNAs are the
functional intermediates of the pathway, which are responsible for performing site-
specific, endonucleocytic cleavage of complementary mRNAs (62, 176, 205). The
process is more complicated in worms, where an RNA-dependent RNA polymerase is
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involved in the production of siRNAs for RNAi (142, 166).  With these results in place,
molecular biologists were off and running with this new technique to experimentally
induce RNAi in their model system for the examination of a specific gene of interest.
Intuitively, it would seem that RNAi would not be a conserved mechanism used
in mammals because of their aforementioned non-specific response to dsRNA.  Previous
studies had demonstrated that PKR is activated by dsRNA of 30 nucleotides or longer
(115).  However, as components of the RNAi response were identified, many of these
factors were found to be conserved in mammals (15, 63). Indeed, mammalian cells were
shown to retain RNAi capabilities, as studies in murine embryonic cell lines lacking a
PKR response demonstrated efficient RNAi generated by long dsRNA (19).  While this
result from a specialized, seldom-studied cell line provided evidence that mammals
maintained an RNAi response, it didn’t translate into efficient use of experimentally-
induced RNAi to study gene function, since most mammalian cell lines commonly used
in laboratory research do maintain the non-specific dsRNA response. However, this
limitation was circumvented when it was demonstrated that the introduction of siRNA
directly into mammalian cells produced specific gene silencing without immune
induction (35).
These initial studies of RNAi uncovered many of the key components conserved
in RNA silencing pathways and provided a basic mechanistic framework for RNA
silencing mechanisms.  As the field expanded, so too did the number of identified RNA-
based triggers, including several RNA species encoded by the host.
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miRNAs and endogenous small RNAs
The aforementioned genetic screen in C. elegans, which uncovered a small
hairpin regulatory RNA that regulates the expression of a heterochronic gene in a post-
transcriptional fashion is now credited as the initial discovery of a micoRNA (miRNA)
(93).  Soon after the initial discovery of RNAi, there were a series of studies describing
large classes of phylogenetically-conserved, endogenously-expressed substrates for RNA
silencing pathways (86, 88, 92).  Studies of these genes have identified them as important
regulators of gene expression, impacting a variety of cellular pathways including cell
death, development, proliferation, and hematopoiesis. They are commonly described as
regulators which “fine tune” gene expression (3, 11). These genes are initially processed
from their hairpin precursors into siRNA-like molecules.  However, unlike siRNAs,
which specifically cleave their targets, miRNAs typically regulate their target genes by
translational repression through conserved miRNA target sites in the 3´UTR of target
mRNAs (3, 179).  However, exceptions to this general rule exist, as examples of several
human miRNAs and numerous plant miRNAs have been shown to perform direct
cleavage of their targets (108, 197). To date, miRNA have been found in all metazoans
examined.  It has been demonstrated that the “seed” sequence of the miRNA (nucleotides
2-7/8) are the critical determinants for target recognition in the 3´UTR of mRNA.
Amazingly, just 15 years ago, miRNAs had not been discovered, yet bioinformatic
analysis now predicts that miRNAs regulate the expression of 30% of all human genes
(100).  More recently, global analysis of miRNA and mRNA expression patterns
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indicates an intricate evolutionary relationship of miRNAs and mRNAs bearing target
sites for these miRNAs.  It was seen that mRNAs bearing conserved target sites for
miRNAs were often expressed at early developmental stages prior to expression of
miRNAs.  Additionally, genes expressed at similar times in similar cells as miRNAs have
evolved to selectively avoid the presence of potential non-conserved target sites in their
3´UTRs (38).
In addition to miRNA, several other classes of endogenously-expressed small
RNAs have been described.  Some of these endogenous small RNAs are similar to the
exogenously-produced siRNAs of long dsRNA triggers, whereas other small RNAs have
slightly larger sizes and enter into distinct silencing complexes (82).  Naturally occurring
siRNAs (Nat-sRNAs) of plants, or endogenous siRNAs (endo-siRNAs) of worms have
been observed.  These RNAs are believed to derive from the production of dsRNA
created by annealing of endogenous sense and antisense transcripts (20, 94).  The trans-
acting siRNAs (tasiRNAs) of plants are derived from dsRNAs created by an RDRP using
endogenous transcripts as its template.  Interestingly, the siRNAs created by this process
regulate different (trans) genes than the one from which the dsRNA was created (144).
Studies in fruit flies uncovered a further class of small RNAs, called repeat-associated
RNA (rasiRNAs), which are derived from repetitive sequence elements in the genome.
These small RNAs are slightly larger in size than siRNAs and associate with different
effector proteins (7, 8, 107, 178).  And, very recently, a subset of small RNAs of ~26-31
nucleotides has been identified in mammalian testes.  These so called piRNAs (PIWI-
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interacting small RNAs), like siRNAs, can perform cleavage of a target RNA in vitro, but
their biological function is currently unknown (82, 89).
Common components of the siRNA and miRNA silencing pathways
The miRNA and siRNA pathways are mechanistically similar and share many
common components (Fig. 1.5).  A considerable amount of cross talk between the
pathways exists, as it has been experimentally demonstrated that siRNAs can be forced to
act like miRNAs, causing translational repression of a target; conversely, miRNAs have
been demonstrated to act as cleaving siRNAs, both in vitro as well as in vivo (32, 67,
197).  Extensive biochemical analysis of in vitro RNAi-competent extracts from fruit
flies and mammals has greatly helped our understanding of how these pathways work.
The following is a summary of the known factors involved in these pathways in humans,
and the divergence of these pathways in different organisms where appropriate.
Processing of dsRNA substrates into functional small RNAs
Typically, triggers for RNAi/siRNA pathway are exogenously introduced sources
of dsRNA, such as virally-produced dsRNA.  The long dsRNA is recognized and
processed into siRNAs by cellular RNase-III enzyme known as Dicer (15).  In flies, there
are two Dicer proteins, Dicer-1 and Dicer-2.  The latter preferentially dices dsRNA
triggers in the siRNA pathway, while the former is involved in the processing of miRNA
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substrates.  In humans, there is only one Dicer protein, which performs the processing of
both dsRNA and pre-miRNA substrates (98, 127). Plants lead the way in number of Dicer
proteins, as they encode four different Dicer molecules (184). Human Dicer performs
dsRNA recognition and cleavage in conjunction with two cellular protein, TAR RNA-
binding protein (TRBP) and protein activator of protein kinase R (PACT) (26, 80, 96).
Processing by Dicer results in the typical product of RNase III cleavage, leaving
5´phosphates and 2 nucleotide 3´ overhangs (36).  Importantly, these 3´overhangs appear
to be key signatures for preventing recognition of the dsRNA by innate immune factors,
such as PKR, RIG-I, and TLRs.  Conversely, blunt-ended small siRNAs have been
shown to trigger a RIG-I response in mammalian cells (80, 117, 118).  The processed
siRNAs are quickly assembled into the RNAi effector complexes, or RNA-induced
silencing complex (RISC), following their production by Dicer.
The precursor molecules for the miRNA pathway are initially transcribed in the
nucleus as long primary transcripts, called pri-miRNAs.  These pri-miRNAs can contain
one or several pre-miRNA precursors within the transcript.  The RNase III enzyme
Drosha, along with a dsRNA-binding protein called DGCR8 (PASHA in flies), form a
“microprocessor complex” that cleaves the pre-miRNA hairpins from the pri-miRNA
transcripts. The cleaved precursor molecule bears a 2 nucleotide 3´overhang at the site of
Drosha cleavage, as is seen with Dicer cleavage (95, 97). The hairpin miRNAs are now
able to exit the nucleus via the nuclear export factor, Exportin-5 (112, 206). Once in the
cytoplasm, the pre-miRNA is then further processed by Dicer, to produce a mature
miRNA/miRNA*  (microRNA/microRNA “star”) duplex, which is similar in form to
27
siRNAs (53, 65, 98).  The miRNA/miRNA* duplex is extremely transient and is difficult
to detect in vitro, as the mature miRNA is quickly loaded into an active RISC, while the
miRNA* strand is degraded.
RISC complexes and the argonautes
Processed siRNA and miRNA are loaded into the effector complexes of the
pathway, as siRNAs associate into RISC complexes, and miRNAs into so-called miRNA
ribonucleoprotein complex (miRNP).  The transient double strand nature of the siRNA
duplex or the miRNA/miRNA* is quickly resolved upon incorporation into the RISC or
miRNP.  This incorporation of one strand into an active complex requires a strand
selection method.  Normally for siRNAs and miRNAs the mitigating factor involved in
this strand selection is the thermodynamic stability at the ends of the small RNA
molecule (79, 161).  The strand incorporated preferentially into RISC is the one bearing
less thermodynamic stability at it 5´end.  For miRNAs, this is the mature miRNA as
opposed to the miRNA*, and for siRNAs, this is referred to as the  “guide” strand of the
siRNA, with the non-incorporated strand dubbed the “passenger”.
The RISC effector complexes are all characterized by the inclusion of a
Argonaute protein family member.  The Argonautes represent a large family of proteins
that can be phylogenetically separated into five sub-families (143).  It appears that
differing Argonaute proteins are capable of performing different types of RNA silencing.
The Argonaute-2 (Ago-2) protein was shown to be responsible for the site-directed
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cleavage of target RNA in a RISC (105, 126).  Cleavage of the target RNA strand occurs
specifically at the phosphodiester bond on the target RNA located across from
nucleotides 10 and 11 on the corresponding siRNA.  In flies, miRNAs load into
Argonaute-1 (Ago-1)-containing RISCs, and siRNAs load into Ago-2 RISCs (a.k.a
“Slicer”) (127). Dauntingly, C. elegans express 27 different Argonaute proteins, which
are involved in various aspects of RNA silencing (199).  Many Argonaute proteins, such
as D. melanogaster Ago-1, are capable of slicing if provided with the appropriate
substrates.  That Ago-1 miRNP complexes normally don’t slice their targets in vivo is
largely due to the lack of perfect complementarity between the miRNA and target RNA
(32, 61).  The method by which miRNA-directed translational repression occurs is an
area of active debate.  Several studies demonstrated effects on mRNA stability, while
others link translational repression to early termination of translation (179).  Unlike the
Argonautes of Drosophila, it has been formally demonstrated that of the four human
Argonaute family members, only Ago-2 is capable of slicing (105, 126).   Currently, very
little is known about the other human Argonaute family, but some intriguing new data
suggest that Ago-1 may be involved in a mechanism that specifically regulates
transcription (70, 81, 154, 174).  The wide variety of Argonaute proteins highlight the
diversity of the RNA silencing pathways, as distinct Argonautes associate with differing
triggers and elicit several different types of silencing mechanisms.
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The anti-viral role of RNA silencing pathways
It is now becoming apparent that RNA-based silencing systems are the primary
anti-viral defense system for several organisms.  Evidence from C. elegans implicates
RNAi in an anti-viral role, as well as a role in the defense against mobilization of
transposons (78, 193).  Evidence continues to accumulate in Drosophila that RNAi is the
primary anti-viral response (182, 183, 186).  It has been found that ago-2 mutant flies are
highly susceptible to viral infection, and additionally, several RNA-silencing suppressor
proteins have been found in insect viruses (110, 183).  Plants provide the clearest
example of a fully functional anti-viral RNA response.  Plants produce a virus-induced
gene silencing (VIGS) response, producing virus-specific small RNAs that can target
viral RNAs for destruction.  Like worms, plants have the ability to spread their RNA
silencing response from cell to cell, and it has been demonstrated that the plant VIGS
response can lead to a systemic silencing (186, 189).  Additionally, numerous plant
viruses encode RNA silencing suppressors, which target a variety of steps in silencing
pathways, from inhibitors that directly bind small RNAs, to inhibitors that prevent the
silencing signal from spreading through the plant (160, 186, 203).
The relationship of anti-viral RNA silencing mechanisms and their viral
counterparts show great similarity to the nature of the mammalian host/virus interactions.
The silencing response of the host to virus displays the same characteristics of the
mammalian adaptive immune response, in that it is specific, adaptive, and mobile (at least
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in the instance of plants and worms).  Additionally, similar to the numerous methods by
which we observe mammalian viruses counteracting the host immune system, we see
viral pathogens utilizing a wide array of silencing suppressors.
The idea that RNA silencing also plays a role in the host/virus response in
mammals is gaining momentum.  Recently, several virally-encoded miRNAs have been
found in mammalian DNA viruses (54, 57, 146, 147, 171).  Several of these miRNAs
were found to regulate expression of viral genes bearing perfect complementarity to the
miRNA.  These activities generally appeared to aid in the ability of the virus to establish
a chronic infection in the cells.  In addition, several proteins encoded by mammalian
viruses were shown to suppress silencing mechanisms in plants and insect cells (21, 30,
103).  Finally, it was demonstrated that a cellular miRNA was able to restrict the growth
of primate foamy virus (PFV) and that the virus produced an RNA silencing suppressor
that inhibited silencing in mammalian cells and as well as plant cells (91).  These results
point to the possibility that RNA silencing mechanisms may play a role in the
mammalian response to viruses.
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CHAPTER II:
MATERIALS AND METHODS
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A. Cell Culture
HeLa cells (American Type Culture Collection (ATCC)) were maintained in
Minimal Essential Media (Gibco/Invitrogen) with 10% (v/v) fetal bovine serum
(HyClone); human 293 cells (ATCC) and HEL (human embryonic lung fibroblasts;
ATCC) were maintained in Delbucco’s Minimal Essential Media (Gibco) with 10% fetal
bovine serum.
B. Viruses
Adenovirus
Wild-type Adenovirus type 5 was obtained from ATCC, and dl331 is a mutant
Adenovirus strain kindly provided by Thomas Shenk (Princeton University, New Jersey),
which contains a 29 base pair (bp) deletion in the VA RNA1 locus, preventing its
expression (173).  Viruses were propagated in HeLa or 293 cells and purified by
centrifugation through cesium-chloride gradients. Virus titers were determined by
immunohistochemical staining for the adenovirus hexon protein with an anti-adenovirus
antibody (Biodesign International) and visualized by using a 3,3'-diaminobenzidine
substrate kit from Vector Laboratories (24).
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Adenovirus Infections
Prior to infection, cells were washed with phosphate-buffered saline (PBS).  Virus
was added to cells in serum-free media containing 20nM Hepes, pH 8.0, and infections
were performed at 37°C in 5% carbon dioxide (CO2) for one hour.  All experiments in
this work utilized a multiplicity of infection (MOI) of 5 or less (as noted in text).
Following the one hour incubation, virus media were removed and replaced with serum-
containing media and the cells were cultured as described above.  For virus growth curve
experiments, cells were resuspended in PBS containing 10% glycerol.  The samples were
then subjected to 3 freeze/thaw cycles in order to disrupt cells and release virus.  Freezing
was performed in a dry ice/EtOH bath, and thawing occurred in a 37°C water bath.
Samples were then centrifuged for 20 minutes at 13,000 x g at 4°C to pellet cell debris.
The virus-containing supernatant was subsequently used in immunohistochemical titering
protocol described above.
Human Cytomegalovirus (HCMV)
The Ad-169 cell culture adapted strain of HCMV (ATCC) was used in these
studies.  Virus stocks were titered using plaque assay on HELs. Briefly, cells were
infected with a series of virus dilutions.  At 3 hours post infection, virus media were
removed, and cells were overlaid with DMEM containing 0.3% Seaplaque GTG agarose
(FMC) and 0.2% FBS. Agarose overlays were allowed to set for 30 minutes at room
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temperature prior to being placed at 37°C. Seven days after infection, monolayers were
fixed by addition of 100% methyl alcohol and stained with Giemsa stain (Sigma-
Aldrich). Triplicate samples were counted to determine the number of plaques.
HCMV Infections
For the miRNA gene array, an MOI of 3 was used.  Infections were performed as
described for Adenovirus with the exception of a 2 hour infection period for HCMV.
C. In vitro RNAi Reactions
Preparation of RNA Templates for Dicing Reactions
Polymerase chain reaction (PCR) was used to generate dsRNA or structured RNA
templates containing a T7 promoter upstream of the sequence of interest.  The primers
used in this study are listed below.  VA RNA PCRs used the recombinant adenovirus
vector, pAd-Easy (Stratagene), as template.  EBERs PCRs used the pBR322-EBV BamC
fragment (kind gift of Jae Jung, Harvard University) as template.  Alu PCRs used
genomic HeLa DNA as template.  Purified PCR products were precipitated and
resuspended in a volume equivalent to 1/10 of the original PCR reaction.  This
concentrated DNA template is then transcribed and radiolabeled in an in vitro
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transcription reaction (60).  Radiolabeled RNAs are gel purified, precipitated, and
resuspended in water.
Primers for svRNA Dicing Templates
VA RNA I
VARNA IVT5- 5´ GCGTAATAACGACTCACTATAGGGCACTCTTCCGTGGTCTGG 3´
VARNA IVT3- 5´ AAAAAGGAGCACTCCCCCGTTG 3´
VA RNA II
T7 + VA RNA2 5´- 5´ GCGTAATAACGACTCACTATAGGGCTCGCTCCCTGTAGCCG 3´
VA RNA2 3´- 5´ AAAAGGGGCTCGTCCCTGTTTC 3´
ALU RNA
Alu 5´+T7- 5´ GCGTAATAACGACTCACTATAGGGGCCGGGCGCGGTGGCTC 3´
Alu 3´- 5´ TTTGAGACGGAGTCTCGCTCTGTCGCC 3´
EBER
EBER 5´+ T7 - 5´ GCGTAATAACGACTCACTATAGGGGGACCTACGCTGCCCTAGA 3´
EBER 3´- 5´ AAAACATGCGGACCACCAGC 3´
Dicing Assays
In vitro dicing assays were performed using a final concentration of 5-10 nM
radiolabeled substrate.  A typical 10 µl reaction contained the following: 3 µl 40x
reaction mix (60), 5 µl D. melanogaster embryo lysate (Haley 2003), 1 µl water, and 1 µl
50-100 nM uniformly labeled dsRNA (or structured RNA) substrate.  Reactions were
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incubated at 25°C for the indicated times.  Reactions were quenched in 100 µl 2X PK
Buffer (200 mM Tris-HCL, pH 7.5, 25 mM EDTA, 300 mM NaCl, 2% w/v sodium
dodecyl sulfate) and were deproteinized by addition of of 10 µl Proteinase K (E.M.
Merck; 20 mg/ml dissolved in water) with 1 µl glycogen carrier (Roche).  Proteinase K
treatment was carried out at 65°C for 30-60 minutes. The reaction contents were extracted
with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) and RNA was
recovered by precipitation with 3 volumes of absolute ethanol.  Precipitate is then washed
with 80% ethanol and the pellet is dissolved in 20 µl formamide loading dye (98% w/v
deionized formamide, 10 mM EDTA, pH 8.0, 0.025% w/v xylene cyanol, 0.025% w/v
bromophenol blue).  Samples were resolved on 15% denaturing polyacrylamide gels.
Following electrophoresis, the gels were dried under vacuum, and detected by
phosphorimagery.  Dicing assays using recombinant human Dicer enzyme (Gene
Therapy Systems) were performed according to manufacturer’s protocol, and the samples
were then Proteinase K-treated, phenol extracted, precipitated, and resuspended as
described for the embryo extract dicing reactions.
Gel Filtration of RNAi Reactions
A preparative scale dicing reactions (100 µL) was prepared with 50nM
radiolabeled VA RNA I template.  Dicing reaction proceeded for 2 hours at 25°C, and the
reaction was then centrifuged at 13,000 x g to remove cellular debris.  Supernatant (~100
µl) was subjected to chromatography on a Superdex-200 HR 10/30 column (Pharmacia)
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at 0.75 ml/min in lysis buffer using a BioCad Sprint (PerSeptive Biosystems).  Following
the passage of 7.5 ml through the column, sixty 200 µl fractions were collected on a
cooled stage (4°C).  Odd numbered fractions were used for scintillation counting, and
even numbered fractions were Proteinase K treated, phenol extracted and precipitated,
and dissolved in 20 µl formamide loading buffer as described above. Samples were
electrophoresed on a 15% PAGE gel to analyze the distribution of the radiolabeled VA
RNA-complexes in the column.   Additionally, the Superdex-200 column was loaded
with an additional 100 µl of sample containing various size markers (100 µl contained:
88 µl Lysis Buffer (100 mM potassium acetate, 30 mM Hepes-KOH, pH 7.4, 2 mM
magnesium acetate), 2 µl of a 1 µM radiolabeled siRNA, 5 µl ferritin (15 µg/µl), and 5 µl
catalase (15 µg/µl)).
Preparation of Cap-Radiolabeled RNA Templates for Target Cleavage Reactions
RNA templates for target cleavage assays are prepared by PCR and transcribed as
described for the dicing RNA substrates, with the exception that no radiolabeled NTPs
are used for transcription.  A list of PCR primers used to create the target RNA templates
are included below.  The PCR reaction uses the pGL2 luciferase plasmid (Promega) as a
template, along with primers that amplify a portion of the luciferase sequence, as well as
the T7 promoter site at the 5´end of the product and a perfectly complementary sequence
to the miRNA of interest and to the lin41 sequence in the 3´of the product.  Following
transcription of the purified PCR template, the non-radioactive target RNA is
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electrophoresed on a denaturing polyacrylamide gel, and the RNA band is detected and
excised from the gel using UV shadowing.  Following gel purification, the RNA is
precipitated and resuspended in a small volume (10 µl) of sterile water.  The target RNA
is then cap-radiolabeled in a reaction including: 10 pmol uncapped target RNA (in 1.75
µl), 5 µl of [α-32P] GTP (3000 Ci/mmol, 40 mCi/ml, ICN Pharmaceuticals), 1 µl 10x
guanylyl transferase buffer (500 mM Tris-Cl, pH 8.0, 60 mM KCl, 12 mM MgCl2, 25
mM DTT), 0.5 µl of 0.1 mM DTT, 0.25 µl of 20U/µl RNasin (Promega), 1 µl of 10 mM
S-adenosyl methionine (SAM, Sigma-Aldrich) in SAM dilution buffer (5 mM H2SO4,
10% ethanol), and 0.5 µl recombinant, heterodimeric vaccinia virus guanylyl transferase
(Ambion).  Reactions were carried out at 37°C for 1.5 hours.  Free radiolabeled
nucleotides were removed by passing the reaction contents over a G-50 spin column
(Roche).  Target RNA was then gel purified, phenol extracted, precipitated, and
resuspended in a small volume of water.
Primers used for preparation of target RNA templates
miR-VA Target RNA
T7 pGL3-ANR Prm- 5´ GCGTAATACGACTCACTATAGGGGATTACCAGGGATTTCAGTC 3´
miR-VA1 Targ 3´Prm- 5´CCCATTTAGGTGACACTATAGATTTACATCGCGTTGAGTGTA
GAGGTCGACGTCAGACAACGGGGGAGTGCTCCTTTTCCGAAGAGAGGAGTTCATGAT
CAGTG 3´
Dcr Target “A”
T7 + DCR A 5´- 5´ GCGTAATACGACTCACTATAGGGGATAATTATCTGTCATGGAGTG 3´
DCR A + Lin 3´- 5´ CGTTGAGTGTAGAACGGTTGTATAAAAGGGGCTGATTCTTCCCAA
TGCC 3´
Dcr Target “B”
T7 + DCR B 5´- 5´ GCGTAATACGACTCACTATAGGGGAAGCTCTATCCTCCTGAA 3´
DCR B + Lin 3´- 5´ CGTTGAGTGTAGAACGGTTGTATAAAAGGGTCAATATCCAAAGT
GCTGG 3´
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Dcr Target “C”
T7 + DCR C 5´- 5´ GCGTAATACGACTCACTATAGGGGAGCTAAGAGCCCAGACTG 3´
DCR C + Lin 3´- 5´ CGTTGAGTGTAGAACGGTTGTATAAAAGGCTTCAACGTGGAGCTT
ACCAGG 3´
Dcr Target “D”
T7 + DCR D 5´- 5´ GCGTAATACGACTCACTATAGGGGGTAAGCTCCACGTTGAAGTTT
C 3´
DCR D + Lin 3´-5´CGTTGAGTGTAGAACGGTTGTATAAAAGGTCTGCTCAGAATCCAT
CCTGC 3´
Target Cleavage Assays (D. melanogaster embryo and human cell extracts) and Mapping
of the Cleavage Product
Reaction contents for a typical D. melanogaster target cleavage reaction include:
3 µl 40x reaction mix (60), 5 µl D. melanogaster embryo lysate, 1 µl target radiolabeled
RNA (1-10 nM final concentration), and 1 µl synthetic siRNA (25-100 nM final
concentration).  Reactions are carried out at 25°C and were processed as described for
dicing assays.  For reactions using human cell extracts, no synthetic siRNA was added
since extracts were prepared from siRNA-transfected or infected-cell extracts. Typical
reactions for human cell extracts include: 3 µl 40x reaction mix, 5 µl human cell extract,
1 µl target radiolabeled RNA (1-10 nM final concentration), and 1 µl water.  Reactions
were carried out at 37°C, and were then processed and analyzed as described for D.
melanogaster embryo lysate reactions. Experiments using 2´-O-methyl (2´oMe)-derived
oligonucleotide inhibitors for calculating the half maximal inhibition of RISC (IC50) were
performed as described (66). Base hydrolysis was performed by incubating labeled target
RNA in a reaction containing 50 mM (NH4)2CO3, pH 9.5, at 95
oC for varying lengths of
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time (5, 10, and 15 minutes).  RNase T1 (Sigma-Aldrich) digestion was carried out at
varying concentrations of enzyme (0.1 U, 1 U, and 10U) for 10 minutes at 50oC in
reactions containing 25 mM sodium citrate, pH 5.0 and 7M Urea.  Base hydrolysis and
RNase T1 reaction products were Proteinase K treated, phenol extracted, precipitated and
resuspended in formamide loading buffer as described above prior to electrophoresis on
denaturing polyacrylamide gels.
D. Preparation of Human Extracts for in vitro RNAi Reactions
Cells were infected or transfected as described and S10 extracts were prepared
according to the protocol of Dignam and Roeder (31). Cells were scraped and collected in
ice-cold PBS, pelleted by centrifugation at 1200 x g for 10 minutes at 4°C, and washed 2
more times in PBS.  Cells were resuspended in 5 volumes hypotonic Buffer A (10 mM
Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT) and swelled on ice for 5-10
minutes.  The cell suspension was collected at 1500 x g for 10 minutes, resuspended in 2
volumes of Buffer A, then disrupted with ~50 strokes using a Dounce homogenizer
(Kimble/Kontes, Vineland, NJ).  Following homogenization, 1/10 volume of Buffer B
(30 mM MgCl2, 1.4 M KCl, 300 mM Hepes, pH 7.9) was added and the suspension was
centrifuged at 13,000 x g for 20 minutes at 4°C.  The resulting supernatant was dialyzed 2
x 90 minutes against Buffer D (20 mM Tris, pH 7.9, 100 mM KCl, 0.5 mM DTT, 0.2
mM EDTA, pH 8.0, and 20% Glycerol (w/v)) in a dialysis cassette (Pierce Slide-A-
Lyzer, 10,000 MW cutoff).  The extracts were centirifgued once more at 13,000 x g for
20 minutes at 4oC, then aliquoted, flash frozen in liquid nitrogen, and stored at -80 oC.
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E. Northern Blot Analysis
RNA was isolated using Trizol reagent (Gibco/Invitrogen) according to the
manufacturer’s protocol, then DNase treated (Promega) and was resuspended in water.
RNA was quantitated by UV spectrophotometry and aliquots of appropriate amounts of
RNA for gel loading were precipitated with 1/10 volume of 3M sodium acetate and 3
volumes absolute ethanol. The precipitated RNA was resuspended in formamide loading
buffer, then resolved on a 15% denaturing polyacrylamide gel and transferred to Hybond
membrane (Amersham-Pharmacia) in 0.5x TBE in a semi-dry transfer system (Transblot
SD, Bio-Rad) at 20 V for 60 min. The RNA was UV cross-linked to the membrane using
a Stratalinker (Stratagene).  The full length VA RNA probe was prepared by in vitro
transcription of a PCR template as described in for preparation of RNA templates above.
The PCR primers used for construction of the template are listed below.  For all other
Northern blots, RNA (Dharmacon) or DNA (Integrated DNA Technologies, Coralville,
IA) oligonucleotide probes (50 pmol per reaction) were 5´-radiolabeled with
polynucleotide kinase (New England Biolabs) and γ-32P-ATP (NEN).  After labeling,
unincorporated radioactivity was separated from the labeled probe using a Sephadex G-
25 spin column (Roche) and probes were hybridzed to blots in Church’s Buffer (0.5 M
sodium phosphate, 7% SDS, and 1mM EDTA).  Blots were washed at the same
temperature used for hybridization using the following protocol:1 X 20 minutes in 2X
SSC/0.1% SDS, 3 X 20 minutes in 0.2X SSC/0.1% SDS, rinsed briefly in 5X SSC and
exposed to phosphorimager screen (Fuji) and scanned and analyzed using an FLA-5000
phosphorimager (Fuji), Image Reader FLA-5000 version 1.0 (Fuji) and Image Gauge
version 3.45 (Fuji).
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PCR primers for production of full length VA RNA probe
ANR IVT5- 5´GCGTAATACGACTCACTATAGGGAAAGGAGCACTCCCCCGTTG 3´
ANR IVT3- 5´ GGGCACTCTTCCGTGGTCTGG 3´
DNA oligonucleotide primers used for Northern blot analysis
VA1 ProbeA- 5´ TTATCCACCAGACCACGGAAGAGTGCCC 3´
VA1 ProbeB- 5´ CGGTCGTCCGCCATGATACCCTTGCGAAT 3´
VA1 ProbeC- 5´ GGCCGGATCCGGGGTTCGAACCCCGG 3´
VA1 ProbeD- 5´ ATGGATCACGGCGGACGGCCGG 3´
VA1 ProbeE- 5´ TCGACACGCGGGCGGTAACCGCATGG 3´
VA1 ProbeF- 5´ CGCTCCCCCGTTGTCTGACGTCGCACACCTGGGT 3´
tRNA-Ile-ATT Probe- 5´ TGGTGGCCCGTACGGGGATCGA 3´ (64)
RNA oligonucleotide probes used for Northern blot analysis
miR-VA1 probe 5´- AAGGAGCACUCCCCCGUUGUCU-3´
Locked nucleic acid (LNA) probes used for Northern blot analysis
miR-17-5p probe 5´- A+CTA+CCT+GCA+CTG+TAA+GCA+CTT+TG -3´
(“+” denotes a locked nucleic acid modification)
F. miRNA Gene Array Analysis
Global miRNA gene analysis was performed on RNA from mock or Adenovirus
(WT Ad-5)-infected HeLa cells (MOI= 5) and from mock or HCMV (Ad-169)-infected
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HEL cells (MOI=3).  RNA from adenovirus-infected cells was extracted using miRvana
Total RNA Isolation (Ambion) at 24 hours post infection (hpi) and RNA from HCMV-
infected cells was extracted at 48 hours hpi.  Purification of the small RNA fraction and
miRNA gene array was performed by LC Sciences (Houston, TX.).  All known human
miRNA and miRNA* sequences known at the time of the experiment were probed on the
micro array chips.  Additionally, for the adenovirus array, a 1000 nt region of the
adenovirus genome encompassing the VA RNA I and VA RNA II loci (10,320- 11,319,
r-strand reading orientation) was probed using a single base tiling approach utilizing
overlapping, TM-normalized 22 nt probes.  Similar single base tiling probes were used to
analyze the 14 putative HMCV pre-miRNAs reported at the time of this work.  Data was
normalized according to the methods described by Lu et. al (109).
G. Primer Extension
Primer extension using total RNA from HeLa cells infected with wild type Ad-5
was performed with the AMV Reverse Transcriptase Primer Extension System (Promega,
Madison, WI).  Briefly, 100 ƒmol of a 5´-radiolabeled DNA oligonucleotide (5´
GGAGCACTCCCCCGTTGTCT 3´, IDT) was annealed to 5 µg total RNA at 55oC for
20 minutes, and then allowed to cool to room temperature (approximately 10 minutes).
For the extension portion of the reaction, the indicated mixtures of dNTPs (2 mM) and
reaction buffer were added to differentiate the extension product, and 30U of AMV
reverse transcriptase was then added to the reactions, which were allowed to proceed for
1 minute at 42oC.  Reactions were immediately placed on ice and 1 volume of formamide
loading buffer was added to each.  Control reactions containing either no template RNA
or dNTPs for extension were also included.  Additionally, synthetic RNA
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oligonucleotides corresponding to the exact sequences of miR-VA “g” and miR-VA “A”
(5´ GA CAA CGG GGG AGU GCU CCU UU 3´, and 5´ AGA CAA CGG GGG AGU
GCU CCU U 3´, respectively, Dharmacon) were also used as RNA templates to act as
markers for differentiation of the extension products.  Products were resolved on a 20%
denaturing PAGE gel and analyzed by FLA-5000 phosphorimager (Fuji).
H. Transfections (siRNAs, 2´oMe Oligonucleotides, and Plasmids)
Synthetic RNA and 2´-O-methyl oligonucleotides (2´oMe, Dharmacon) were
deprotected and annealed according to manufacturer’s protocol.  Sequences of siRNAs
and 2´-O-methyl oligonucleotides used in these studies are listed below.  The siRNAs
used in this study were designed to bias the loading of the guide strand (g) of the siRNA
into active RISC.  This was accomplished by intentionally creating a mismatch at the
proximal nt at the 5´end of the guide strand/3´passenger strand (p) pairing to produce a
less thermodynamically stable (i.e. asymmetric) end of the siRNA, favoring incorporation
of the guide strand into RISC (161).The human Dicer expression plasmid (pDcr) was the
kind gift of Daryll Conte and Craig Mello (University of Massachusetts Medical School).
This vector contains the full length human dicer cDNA cloned into a pCDNA backbone
(Invitrogen). All transfections were optimized for each cell line (HeLa or 293) according
to the manufacturer’s protocol.  All siRNA and 2´oMe transfections were performed
using Oligofectamine (Invitrogen) and used a final concentration of 25 nM of the
transfected small RNAs.  Plasmid transfections were performed using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocol.
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siRNAs
siLuc (g)  5´ UCGAAGUAUUCCGCGUACGUG 3´
siLuc (p)  5´ CGUACGCGGAAUACUUCGCUU 3´
siDcr (g) 5´ UCCAGAGCUGCUUCAAGCAdTdT 3´
siDcr (p) 5´ UGCUUGAAGCAGCUCUGGCdTdT 3´
siVA “g” (g)  5´ GACAACGGGGGAGUGCUCCUU 3´
siVA “g” (p)  5´ GGAGCACUCCCCCGUUGUCAG  3´
siVA “A” (g)  5´ AGACAACGGGGGAGUGCUCCU 3´
siVA “A” (p)  5´ GAGCACUCCCCCGUUGUCAGG 3´
siDcr Trg A (g) 5´ AGACAACUGCUGUGUAUCUdTdT 3´
siDcr Trg A (p) 5´ AGAUACACAGCAGUUGUCCdTdT 3´
siDcr Trg B (g) 5´ AGACAACAUGAAACCAGACdTdT 3´
siDcr Trg B (p) 5´ GUCUGGUUUCAUGUUGUCCdTdT 3´
siDcr Trg C  (g) 5´ AGACAACAUUGGCGCACUUdTdT 3´
siDcr Trg C  (p) 5´ AAGUGCGCCAAUGUUGUCCdTdT 3´
siDcr Trg D (g) 5´ AGACAACAAAAAACACUGGdTdT 3´
siDcr Trg D (p) 5´ CCAGUGUUUUUUGUUGUCCdTdT 3´
2´oMe Oligonucleotides
2´–O– Luc  5´ CAUCACGUACGCGGAAUACUUCGAAAUGUCC  3´
2´–O– let-7 5´ UCUUCACUAUACAACCUACUACCUCAACCUU  3´
2´–O– miRVA1 5´ UCUUCAAGGAGCACUCCCCCGUUGUCUAUUCC  3´
2´–O– miRVA2 5´ UUCAAGGGGCUCGUCCCUGUUUCCGGAGAUUC  3´
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I. Quantitative Reverse-Transcription Real-Time PCR (qRT-PCR)
Total cellular RNA was prepared using Trizol reagent (Invitrogen) and 1.5 µg
total RNA was reverse transcribed using Sensiscript III and oligo dT (12-18) primer
(Invitrogen) according to manufacturer’s instructions.  qPCR analysis was performed
using QuantiTech Sybr Green PCR Kit (Qiagen Inc., Valencia, CA) and analyzed using a
DNA Engine Opticon 2 (MJ Research [Bio-Rad, Hercules, California]).  Displayed
results are the average of three separate experiments repeated in triplicate.  Sequences for
the real time primers are displayed below and primer set validation was performed for all
three primer sets. Relative mRNA concentrations were calculated by the 2∆∆CT method
(106).
qPCR Primers
GAPDH (s) 5´ GAAGGTGAAGGTCGGAGTC 3´
GAPDH (as) 5´ GAAGATGGTGATGGGATTTC 3´
Dicer (s)  5´ CAGAACGTTGCTCAGCGAGTC 3´
Dicer (as) 5´ GGTTGCACGGGTATTTCCTG 3´
Actin (s)  5´ GCAAAGACCTGTACGCCAACA 3´
Actin (as) 5´ ACACGGAGTACTTGCGCTCAG 3´
J. Protein Extraction and Western Blot Analysis
Following indicated treatments, HeLa or 293 cells were harvested and centrifuged
at 1500 x g for 10 minutes.  Cell pellets were resuspended in ice cold PBS and
centrifuged at 1500 x g for 5 min.  The cells were then resuspended in WCE buffer (55
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mM HEPES, pH 7.9, 275 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 10% Glycerol, 0.01
% NP-40, 1.1 mM DTT, + 1X Protease Inhibitors (Sigma-Aldrich)) and incubated on ice
for 60 minutes.  Following centrifugation at 13,000 x g for 10 minutes at 4oC, the
supernatant was collected and used as whole-cell extract. Proteins were separated by
SDS-polyacrylamide electrophoresis and transferred to a nitrocellulose membrane
(Schleicher and Schuell).  Western analysis was performed using a monoclonal antibody
for Dicer (Clonegene) at a dilution of 1:150 and a secondary HRP-conjugated goat anti-
mouse antibody (Amersham-Pharmacia) at a dilution of 1:10,000.  Equal loading was
confirmed using antibodies to detect α-tubulin (Santa Cruz Biotechnology) at a dilution
of 1:500 and a secondary HRP-conjugated goat anti-mouse antibody (Amersham-
Pharmacia) at a dilution of 1:10,000.  Blots were detected using ECL reagent (NEN) and
quantified using an LAS-3000 phosphorimager (Fuji, Tokyo, Japan).
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CHAPTER III:
ADENOVIRUS VA RNA IS A
SUBSTRATE FOR CELLULAR RNA
SILENCING PATHWAYS
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Introduction
The initial groundbreaking studies of RNA silencing phenomena in the 1990s has
led to a massive amount of research directed at uncovering RNA silencing activities in a
wide array of organisms (40, 135). These diverse organisms have evolved to use several
related components of RNA silencing for a variety of applications, from host defense
against pathogens to biogenesis of small RNAs that are critical regulators of gene
expression.  Not only do these pathways vary from organism to organism, but they also
diverge in each species in relation to the substrate or trigger RNA being examined (204).
Plants, for example, have related, but distinct pathways to handle dsRNA triggers from
viruses, single strand triggers from transgenes, and several overlapping pathways to
handle the wide array of endogenously produced small RNAs (184). It is becoming
apparent that nearly any RNA sequence bearing a hairpin or extensive secondary
structure may be a substrate for an RNA silencing pathway.
Along these lines, numerous viruses encode structured RNA molecules that have
the potential to come into contact with host RNA silencing pathways during the virus life
cycle.  Examples of highly structured RNAs produced during viral infections include
small RNA molecules transcribed during replication, such as the adenovirus VA RNAs,
and Epstein-Barr virus EBERs, as well as large structured portions of viral genomes or
transcripts, such as human immunodeficiency virus (HIV) TAR sequences and the
internal ribosome entry sites (IRES) of RNA viruses.   We theorized that since RNA
silencing was shown to act as an immune defense system in plants and lower animals, it
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was likely that similar RNA silencing pathways may also be actively involved in the
virus-host interaction for mammals.  In taking a candidate-based approach to look for
viral RNAs that enter into cellular RNA silencing pathways, we chose to study the VA
RNA I molecule of adenovirus.  This highly expressed, RNA polymerase III-transcribed
RNA has been previously shown to play a crucial role in viral replication by blocking the
robust interferon-inducing PKR response in mammals.  Interestingly, VA RNA
molecules display a gross resemblance to the predicted secondary structures of pre-
miRNA molecules, known substrates for RNA silencing.  Additionally, VA RNA utilizes
the same nuclear export factor, Exportin-5, that pre-miRNAs use to traffic from the
nucleus to the cytoplasm (59).  These factors led us to hypothesize that adenovirus VA
RNA molecules may act as substrates for host RNA silencing machinery in a similar
fashion to dsRNA molecules or pre-miRNAs.
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Results
Adenovirus VA RNA I is diced to produce small RNAs
Recent studies in plants, insects, and worms have established RNA silencing
pathways as integral components of a host response to pathogens (186). In plants, dsRNA
created during viral replication can lead to a virus-induced gene silencing (VIGS)
response and the production of small RNAs that specifically target viral transcripts (188).
Additionally, the Tombusvirus was shown to encode a suppressor of RNA silencing, p19,
that binds and sequesters siRNAs (196).  These studies indicated that Dicer family
proteins were important members of the RNA silencing response to viruses in plants.  As
such, we decided to test whether a structured RNA from a mammalian virus may be a
substrate for Dicer cleavage.  For our initial analysis, we chose to test the adenovirus VA
RNA I molecule, a highly structured, ~160 nucleotide RNA produced by RNA
polymerase III transcription.  In vitro-transcribed, radiolabeled VA RNA I was tested for
its ability to be diced in D. melanogaster embryo lysate and in an in vitro reaction with
recombinant human Dicer enzyme (Fig. 3.1).  Our results demonstrate that both the
RNAi-competent fly extract and the recombinant Dicer enzyme are able to efficiently
process small RNAs characteristic of RNA silencing from the VA RNA molecule.
To more closely examine the production of VA-specific small RNAs in fly
extract, we performed a large scale dicing reaction and fractionated the contents by gel
filtration on a Superdex-200 column.  Previous work had demonstrated specific peaks of
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22 nt —
Fig. 3.1: VA RNA I is diced to produce small RNAs.
Radiolabeled VA RNA I was incubated for the indicated times in RNAi-
competent D. melanogaster embryo lysate (Fly) or  an in vitro reaction with 
recombinant human Dicer (rDcr) enzyme (Gene Therapy Systems).  RNA 
was electrophoresed on 15% polyacrylamide gel to detect presence of 
processed small RNAs.
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protein/siRNA complexes (siRNP) associated with RNAi activity in specific column
fractions (137). When VA RNA was processed in an RNAi reaction and separated on the
column, we observed a peak of both full-length VA RNA molecules and VA-specific
small RNAs (~21 nt) at an apparent molecular weight of 220-230 kD (fraction 17) (Fig.
3.2).  This correlates well with the predicted size of D. melanogaster Dicer-2 protein, and
also coincides with the fractions previously identified for siRNP formation (137). When
unprocessed, radiolabeled VA RNA or siRNA (not incubated in the fly extract) was
loaded and fractionated on the column, the RNAs accumulated in lower molecular weight
fractions, indicating that the VA RNA in our dicing reaction was bound, and presumably
cleaved, in larger ribonucleoprotein complexes (data not shown).  Additionally, a second
peak of VA-specific small RNAs was observed in fractions 39-43, which were previously
identified as fractions supporting siRNA-based target cleavage (137).  Although not
functionally demonstrated in our assay, we can speculate that this peak of small RNAs is
reflective of VA-specific small RNAs loaded into an argonaute-containing RISC
complex.
VA RNA-specific small RNAs accumulate in infected cells
In order to determine whether the previously observed in vitro production of VA-
small RNAs was relevant to adenovirus infection, we performed northern blot analysis to
look for the presence of these small RNAs in infected cells.  HeLa cells were infected
with wild-type adenovirus (Ad-5) at varying multiplicities of infection (MOI), and RNA
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Fig. 3.2: VA-specifc small RNAs appear to co-fractionate with RNAi components.
The contents of a large scale dicing reaction containing radiolabeled VA RNA was
fractionated on a Superdex-200 gel filtration column.  RNA was isolated from the 
odd numbered fractions and analyzed on a 15% polyacrylamide gel.  The signal intensity of 
full length VA RNA and VA-specific small RNAs in each fraction are plotted above.
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was examined for VA RNA-specific small RNAs, using a probe complementary to the
full length VA RNA molecule.  We observed the presence of VA-specific small RNAs of
approximately 21-22 nucleotides in the infected cells (Fig. 3.3).  This result indicated that
VA RNA may indeed be a substrate for host RNA silencing pathways in vivo and that
this interaction may be important to the process of infection, the host response to virus, or
both.
To further delineate the region of the VA RNA I molecule producing the small
RNAs, we performed northern blot analysis using a series of overlapping oligonucleotide
probes, which span the entire VA RNA molecule (Fig. 3.4).    The region of VA RNA I
that gives rise to the 21-22 nucleotide small RNAs occurs in the 3´ end of molecule, in
the descending arm of the terminal stem (probe F, Fig. 3.4).  These small RNAs are
similar in size to those seen by the in vitro dicing assays (Figs. 3.1 & 3.2) and those seen
in the northern blots using the full length VA probe (Fig. 3.3).  We dubbed this VA-
specific small RNA “miR-VA”, due to its similarity in size to miRNAs, and because it
appeared to accumulate asymmetrically, as has been reported for miRNAs (79, 161).
That is, we saw the 21-22 nt miR-VA accumulate in infected cells with probe F, but did
not see the corollary 21-22 nt miRNA* strand when performing northern analysis with
probe A.  Interestingly, several of the other probes (A, B, D) also detected small RNA
products of a size slightly larger than that characteristic of siRNAs and miRNAs.
Whether or not these represent functional small RNAs or by-products of enzymatic
cleavage or degradation remains to be determined.  Recently, several other groups have
similarly reported the production of small RNAs from the VA RNA locus (4, 6, 158).
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Fig 3.3: VA RNA-specific small RNAs are produced in infected cells. 
HeLa cells were mock-infected (M) or infected with increasing MOIs of wild 
type adenovirus.  RNA was harvested at 24 hours post-infection and northern 
blots were probed with a radiolabeled full length, anti-sense VA RNA probe.  
Markers include a radiolabeled 22 nt. siRNA, and RNA from an in vitro VA 
RNA dicing reaction using non-radiolabeled VA RNA as substrate.
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Fig 3.4: VA RNA-specific small RNAs map to the 3 e´nd of the VA RNA molecule.
HeLa cells were mock-infected or infected with increasing MOIs of wild type
adenovirus.  RNA was harvested at 24 hours post-infection and northern blots were 
probed with overlapping, radiolabeled, antisense oligonucleotide probes as indicated.  
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We further analyzed the production of the miR-VA in infected cells by following
its accumulation over the early stages of an infection.  Previous experiments indicated
that in our experimental system, full length VA RNA reached its peak accumulation by
24-30 hours post-infection (hpi).  In order to examine the relative levels of miR-VA and
VA RNA accumulation, we performed northern blot analysis on RNA extracted during
the first 18 hours of infection (Fig. 3.5).  From our analysis, it appears that miR-VA
accumulates early in infection and is detected at similar levels to full length VA RNA at 3
hours post-infection.  While the level of VA RNA quickly rises to extraordinarily high
levels in infected cells, the level of miR-VA appears to level off rather quickly.  During
this initial 18 hour analysis, the level of miR-VA does not appear to exceed 10% of the
level of full length VA produced.  However, since it has been reported that up to 108
molecules of VA RNA I can accumulate in infected cells, this small percentage of miR-
VA could still represent an impressive and potentially significant amount of viral miRNA
in the infected cells (121).
Mapping of the miR-VA molecule reveals the presence of multiple miR-VA species
Because miR-VA seemed to accumulate asymmetrically in infected cells, we
sought to determine the precise identity of miR-VA with the goal of using this
information to identify potential targets of the putative miRNA.  We employed several
different strategies in order to determine the exact sequence of miR-VA.  In the first
technique, the small RNA fraction from Ad-5 infected cells was subjected to single-
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Fig. 3.5: miR-VA1 accumulates during infection.
HeLa cells were infected with WT Ad-5, total RNA was collected at the indicated 
times, and northern blots were probed with a miR-VA specific oligonucleotide RNA  
probe.  Accumulation of full length VA RNA molecule (closed circles) was compared 
to that of miR-VA (open circles) (B).  Each data point is internally normalized to the 
control tRNA level, and the data points were then normalized to the level of VA RNA 
at 3 h.    
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nucleotide, hybridization-based, tiling analysis with microarray detection (LC Sciences),
using a series of 22 nucleotide TM-normalized probes.  The overlapping series of tiling
probes differ by a single nucleotide, as each probe is “n+1” of the preceding probe.
These TM-normalized probes provide adequate sensitivity to differentiate between a
probe bearing perfect complementarity to a miRNA and another probe bearing only a
single mismatch with the miRNA of interest (LC Sciences, (178). We performed this
tiling analysis to examine all small RNAs potentially produced from nucleotides 10,320-
11,319 on the right-reading strand of the Ad-5 genome, and the corresponding
nucleotides on the left-reading strand (Fig. 3.6).  The VA RNA I and II genes reside on
the right-reading strand at nucleotides 10,620-10,779 and 10,876-11,038, respectively.
As seen in the tiling analysis of the right-reading strand, the highest signal detection
occurred between nucleotides 10,749-10,777, which corresponds to the region identified
as being responsible for production of miR-VA by our northern blot analysis (Fig. 3.5).
The exact sequence detected by this probe corresponds to nucleotides 10,756-10,777.
The tiling analysis also revealed high levels of VA-specific small RNA detection in the
5´end of VA RNA I in the ascending arm of the terminal stem, as well as the ascending
arm of the apical stem.  This is also in accordance with the northern blot analysis using
the overlapping oligonucleotide probes (Fig. 3.4), which detected small RNAs with
probes A and B.  The small RNAs from the ascending arm of the terminal stem detected
in the tiling experiment and by probe A in northern blots (Fig. 3.4) is likely to result from
dicer cleavage of a miR-VA/miR-VA* duplex produced from the terminal stem.  The
tiling analysis additionally demonstrates that small RNAs are produced from the VA
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RNA II locus (Fig. 3.6).  The peak signals again corresponded with the 5´and 3´termini of
the molecule, raising the possibility that a miR-VA2/miR-VA2* duplex is produced by
the VA RNA II locus.  All microarray tiling was also performed on mock- infected RNA
samples to ensure that the peaks identified in the infected-cell RNA were specific to the
virus.  The tiling analysis of the left-reading strand revealed very few peaks specific to
virus and those peaks were of much lower intensity than those seen in the right-reading
strand.  The very high level of signal detected throughout the VA RNA loci may result
from the detection of full length and/or truncated or cleaved VA RNA molecules, since
the small RNA fraction can contain double stranded nucleotides of ~125 nucleotides or
less.
To distinguish the precise 5´end of miR-VA, we performed primer extension
analysis on RNA from infected cells.  We analyzed several primers to define the
approximate end of miR-VA (data not shown), and then performed an extensive analysis
with a primer that produced a 2-3 nucleotide extension product.  The results indicated
that miR-VA appears to have two major products in infected cells, with those miRNAs
differing by a single nucleotide at the 5´end of the molecule (Fig. 3.7 A).  The 5´end of
these miRNAs map to nucleotides 10,756 and 10,757 of the Ad-5 genome.  We referred
to these miRNAs as miR-VA “A” and miR-VA “g” based on the identity of the proximal
5´nucleotide of each miRNA.  Extension reactions using only the two nucleotides
involved in the extension (dTTP, dCTP, or both) confirmed the identity of the extension
product seen in the reaction when all dNTPs are present.  Control reactions lacking either
total RNA template or dNTPs confirmed the specificity of the extension (Fig. 3.7 A).
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Further confirmation of the precise extension products was seen in reactions using
synthetic RNA templates comprising the exact miR-VA “g” and miR-VA “A” sequences
(Fig. 3.7 B).  These control reactions indicated that our primer extension protocol was
revealing authentic extension products and that the presence of multiple products in the
total RNA samples was not the result of a non-templated nucleotide addition by the
enzyme.  These primer extension reactions indicated that there are two major miRNAs
(miR-VAs) produced from the 3´end of VA RNA I.  This is in accordance with our
dicing assays and northern blot analysis, which both displayed several products in the
small RNA size range.  Interestingly, two other groups identified miR-VAs by different
techniques, with one of these groups identifying miR-VA “g” as the authentic miR-VA
and the other group characterizing miR-VA "A" as the predominant miR-VA produced
(6, 158).
 miR-VA is an authentic miRNA that enters RISC
We further explored the interaction of VA RNA with the RNA silencing pathway
by determining whether miR-VA proceeded from Dicer cleavage into the next stage of
the RNA interference pathway, assembly into a functional RISC complex. In D.
melogaster, as a general rule, siRNAs segregate into slicing competent Ago2-RISC
complexes, while miRNAs enter non-slicing Ago1-RISC complexes (140). There are four
members in the human argonaute subfamily (Ago1-4), and it has been shown that
siRNAs and miRNAs can associate with all four of these argonaute proteins; however,
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only Ago2 (Slicer) has been shown to be capable of performing target cleavage (105,
126).  Therefore, we established an in vitro cleavage assay to determine if miR-VA
resided in an Ago2-containing RISC complex, which could slice a perfectly
complementary target.  We constructed a cap-labeled target RNA molecule containing a
sequence that bore perfect complementarity to miR-VA.  This target RNA was then
incubated in an in vitro RNAi reaction containing extract from mock-infected or
adenovirus-infected HeLa cells (Fig. 3.8 A).  In this setting, specific target cleavage
would only result from miR-VA loaded into Ago2-RISC complexes in vivo, prior to
preparation of the extract.  We found that in the WT Ad-5-infected extracts, specific
cleavage of the target RNA occurs in the region corresponding to miR-VA.  This
cleavage product does not accumulate in mock-infected extracts, and more importantly,
in the dl331 (∆VA1)-infected extracts.  The dl331 adenovirus is a mutant virus containing
a deletion of the VA RNA I gene (173). Therefore, the observed cleavage in the WT Ad-
5 extracts is specific to VA RNA I.  To further establish the specificity of the miR-VA
region of the molecule as being responsible for the slicing of the target, we performed
related cleavage experiments using a specific inhibitor of miR-VA.  It has been shown
that antisense oligonucleotides composed of nucleotides with 2´-O-methyl (2´oMe) base
modifications are highly efficient, stable, and specific inhibitors of small RNA function
(66). We repeated our target cleavage analysis in WT Ad-5-infected extracts using
increasing concentrations of a specific 2´oMe inhibitor of miR-VA (Fig. 3.8 B).  As the
concentration of the inhibitor is increased, the level of target cleavage (measured as
66
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(product/substrate+product)) decreased, indicating that the cleavage was specific to miR-
VA.
miR-VA "g" resides in Ago2 RISC
The in vitro cleavage assay indicated that only a single cleavage product
accumulates, rather than two distinct products resulting from miR-VA "g" and miR-VA
"A"-generated slicing.  In order to distinguish which miR-VA was responsible for Ago2-
mediated target cleavage, we mapped the cleavage product using a long polyacrylamide
sequencing gel.  Marker lanes included the target RNA subjected to RNase T1, which
cleaves RNA at guanosine residues, as well as a lane containing target RNA subjected to
base hydrolysis in alkaline conditions.  Resolution of the precise scissile phosphate at
which target cleavage occurs allows for the determination of the small RNA responsible
for the cleavage, since it has been demonstrated that target cleavage occurs at the
phosphate opposite of nucleotides 10 and 11 of the miRNA guide strand (65, 105, 126,
169)).  Therefore, by identifying the precise nucleotide at which cleavage of our target
RNA occurs, we were able to extrapolate the 5´ end of the cleaving miR-VA, which maps
to miR-VA "g" (Fig. 3.9).  To confirm this mapping, we prepared extracts from HeLa
cells transfected with siRNAs corresponding to the exact guide strand sequences of miR-
VA "g" and miR-VA "A".  These extracts were used to perform similar in vitro cleavage
assays, and they generated specific cleavage products of the expected sizes (data not
shown).  When the products of these cleavage reactions were electrophoresed on a long
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polyacrylamide sequencing gel alongside the products of cleavage assays performed in
the WT Ad-5-infected extracts, we saw that the infected cell cleavage product migrated to
the same position on the gel as the product from the siVA “g” transfected extracts (Fig.
3.10).  This product was discernibly one nucleotide shorter than the product generated in
the siVA “A” transfected extracts.  When portions of these reactions were mixed, the
siVA “g”/WT mixture produced only a single cleavage product, while the siVA “A”/WT
mixture produced two distinct products (Fig. 3.10).  These results indicate that miR-VA
"g" produced in infected cells forms an Ago2-associated RISC complex capable of
cleaving a target RNA, while miR-VA "A" does not appear to enter a slicing-competent
complex.  Furthermore, several other groups have reported that miR-VAs can regulate
RNAs containing miR-VA target sites in cell culture using luciferase-based reporters (4,
6, 158).
Structured small RNAs related to VA RNA I are processed to small RNAs
Since we determined that VA RNA I was a substrate for Dicer and that it enters
into the RNA silencing pathway, we chose to look at several other structured RNAs,
including the VA RNA II molecule of adenovirus, the Epstein-Barr Virus (EBV) EBERs,
and Alu RNA, a human genetic short, interspersed element (SINE). The EBV EBERs are
small RNAs transcribed by RNA polymerase III.  They have been shown to perform
similar PKR-inactivating functions to VA RNA, and they can functionally substitute for
adenovirus lacking VA RNA (18). Alu SINES make up roughly 10% of the mass of the
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human genome and when transcribed, they produce structured RNAs of ~300 nucleotide
and Alu sequences (12).  They are derivatives of 7SL RNA genes and are believed to
have originated in primates 65 million years ago (134, 177).  It is believed that
retrotransposition of these elements can occur following RNA polymerase III
transcription (12).  Interestingly, like VA RNA, Alu RNAs have been shown to stimulate
translation of co-expressed plasmids in cell culture transfections (157).  We constructed
radiolabeled transcripts for VA RNA II, EBERs RNA, and Alu RNA to test in our in
vitro dicing assays.
Our previous microarray tiling experiment and northern blots provided indications
that VA RNA II produced small RNAs during infection.  When we incubated VA RNA II
in our dicing assays, we observed the production of small RNAs characteristic of RNA
silencing phenomena (Fig. 3.11).  The production of these small RNAs appears to be less
efficient than those produced from the VA RNA I substrate.  Similarly, northern blot
analysis revealed very weak expression of VA RNA II-specific small RNAs (data not
shown).  The production of these small RNAs was increased slightly in dl331 (∆VA1)
infected cells, which produce higher levels of VA RNA II to compensate for the absence
of VA RNA I (42). However, our repeated attempts to identify miR-VA2 specific
cleavage in our in vitro cleavage assay were unsuccessful (data not shown).
Nevertheless, our dicing assays, northern blot analysis, and microarray tiling data suggest
that VA RNA II may produce functional miRNAs.  Indeed, recent data suggests that
small RNAs derived from VA RNA II can cleave in vitro targets and regulate luciferase-
based VA RNA II targets in cell culture (4).
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Fig 3.11: VA RNA I and VA RNA II are processed to small RNAs indicative of RNA 
silencing.
Radiolabeled VA RNA I and VA RNA II was incubated in in vitro reactions with either 
RNAi-competent D. melanogaster embryo extract or recombinant human dicer enzyme 
as in Fig. 3.1.
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We also performed our in vitro dicing assay using the EBV EBERs and Alu RNA
as substrates.  We again saw that small RNAs of ~21-22 nucleotides could be produced
from these substrates (Fig. 3.12).  The efficiency of dicing for both molecules was again
much lower than that seen with VA RNA I.  Follow up experiments using northern blot
analysis were unable to detect any EBER-specific RNA in EBV infected cell lines.
Similarly, attempts to detect Alu-specific small RNAs by northern blot analysis in several
cell lines were unsuccessful (data not shown).  Studies indicate that Alu RNAs are
expressed when cells are stressed, so it would be prudent to repeat our analysis under
such conditions (157). While it is tempting to speculate that these substrates can produce
functional small RNAs, it is also likely that a wide variety of structured RNAs may be
cleaved by Dicer or Dicer-like enzymes in Drosopila extract or that the recombinant
Dicer enzyme may cleave structured RNAs in an indiscriminant fashion.  Further
experiments are needed to address whether these and other viral and cellular structured
RNAs enter into RNA silencing pathways.
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Discussion
Adenovirus VA RNA enters the RNA silencing pathway
Our studies show that VA RNA I enters into the mammalian RNA silencing
pathway, as it can be processed to small RNAs by Dicer, and enters into a functional
RISC in vivo.  Additionally, it had been shown that VA RNA and pre-miRNAs utilize the
same nuclear export factor, Exportin 5, to transit to the cytoplasm (59, 111, 112, 206).
These studies, combined with our data, indicate that VA RNA interacts with at least three
protein complexes involved in RNA silencing during infection.
The initial dicing assays we performed demonstrated that VA RNA I is a
structured RNA substrate that is efficiently processed to small RNA species by Dicer
(Fig. 3.1).  The chromatography of the in vitro dicing reaction further revealed that VA
RNA appears to be processed by a Dicer-associated complex based upon the fractions
with which the VA-specific small RNAs co-fractionated (Fig. 3.2, (137)).  Additionally,
this experiment provided an indication that these small RNAs may proceed further into
the RNAi pathway, since an additional peak of small RNAs occurred in fractions
previously identified to contain RISC activity (137).
Importantly, we demonstrated that these small RNAs were not artifacts of in vitro
processing assays, as we utilized several nucleotide-based detection methods to identify
the presence of the small RNAs in infected cells.  Using overlapping probes for northern
blot analysis, we identified the 3´end of the molecule as the progenitor of the 21-22
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nucleotide small RNAs, miR-VAs, seen in infected cells (Fig. 3.4).  When analyzing the
accumulation of the miR-VA in infected cells, we saw that it was detectable very early
after infection (3 hours), but that the accumulation of miR-VA quickly leveled off, while
the production of full length VA RNA continued to steadily increase (Fig. 3.5).  This may
reflect saturation of components required for miRNA biogenesis in the cell.  Indeed,
although less than 10% of VA RNA appears to be converted to miR-VA, this may still
represent a very large pool of miR-VA, since such massive quantities of VA RNA are
produced in infected cells.  Alternatively, full length VA RNA production may occur at
the expense of miR-VA at later times in infection, when VA RNA-based inactivation of
PKR becomes necessary, as dsRNA intermediates are being produced during virus
replication (116).
We additionally performed microarray-based single nucleotide tiling analysis of
the portion of the Ad-5 genome encoding the VA RNA I and II genes (Fig. 3.6).  This
analysis revealed distinct peaks of small RNA detection that coincided with the regions
we had previously mapped by northern analysis (Fig. 3.4 & 3.5).  Peaks corresponding to
the terminal stem of both VA RNA I & II were identified, with the highest signal
occurring at the region we had previously identified as miR-VA.  This data indicated that
the terminal stems of VA RNA molecules may act as a pre-miRNA which gives rise to
miR-VA/miR-VA* duplexes.
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VA RNA I encodes a miRNA
The demonstration that infected cell extracts could perform miR-VA specific
target cleavage provided evidence that miR-VA acts as an authentic miRNA, which
enters into an Ago2-RISC complex (Fig. 3.8).   Concurrent studies by another group
speculated that VA RNA acted as a competitive inhibitor of Dicer, with its goal being to
prevent Dicer-mediated cleavage of viral RNA or cellular pre-miRNAs (111). However,
our work demonstrated that the interaction of Dicer with VA RNA produced a functional
miRNA molecule that was capable of regulating target RNAs.  Additional target cleavage
studies indicate that the putative miR-VA* was also capable of cleaving a complementary
target in vitro (data not shown).  Related studies by other groups provided evidence that
small RNAs produced from VA RNA could regulate target RNAs both in vitro and in cell
culture (4, 6, 158).
We further extended our analysis of miR-VA by deciphering the precise 5´
terminus of the miRNA.  Elucidation of the mature miRNA sequence could aid in the
identification of cellular or viral targets for the miRNA.  Our primer extension analysis
revealed the presence of two distinct miR-VA species, miR-VA "g" and miR-VA "A",
which differed by a single nucleotide at the 5´of the miRNA, with miR-VA "A" being
n+1 of the miR-VA "g" sequence.  These miRNAs were described independently in two
other studies, with one group claiming miR-VA "g" as the miRNA product, and the other
group describing miR-VA "A" as the major product (6, 158)).  It is possible that miR-VA
“g” inhabits an Ago2-RISC, while miR-VA "A" is loaded into a different argonaute
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family member.  To this point, very little is known about the function of the other human
argonaute proteins.  The identification of two miRNA species is consistent with the
presence of multiple VA RNA dicing products and multiple miR-VA specific products
being detected by northern blot analysis (Figs. 3.1 and 3.4).  Additional heterogeneity of
miR-VA sizes may be introduced at the 3´end of the molecule, since the miR-VA
sequence extends into the poly-uridine (poly-U) tract of nucleotides at the 3´terminus of
VA RNA.  This poly-U stretch is the result of the RNA polymerase III termination signal
(a run of adenosine residues in the template), and VA RNAs with variable length poly-U
sequences at their 3´termini have been described (25).
Intriguingly, phylogenetic analysis of a wide cohort of VA RNA genes from
adenovirus subfamilies indicates that the region of the molecule containing the miR-VAs,
the terminal stem, is the most conserved at the sequence level (114).  The main function
ascribed to VA RNA is its inhibition of PKR activation, and further studies demonstrated
that it was the apical stem and central domain of VA RNA that were responsible for the
binding and inactivation of PKR, respectively (27, 44, 46, 128-130, 173).  It is somewhat
surprising that these regions are not the most conserved portion of the VA RNA
molecule, since they are responsible for such a crucial activity during infection.
Additionally, mutational analysis of the miR-VA region of VA RNA demonstrated that
viruses deleted for the region encoding miR-VA or containing mutated sequences in the
miR-VA region grew very poorly in comparison to wild type virus and other viruses
containing mutations in the apical stem and central domain (16, 44).  It therefore seems
likely that binding and inactivation of PKR is dependent upon the secondary structure of
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VA RNA, and is not solely reliant on the primary sequence of the molecule. It is tempting
to speculate that the terminal stem is the most highly conserved region of the molecule
because it contains the miR-VA sequence.  Also, the fact that virus mutants bearing
interrupted or mutated miR-VA sequences have dramatic effects on virus growth gives
credence to the idea that the miR-VA may be of crucial importance for the ability of the
virus to replicate (16, 44). However, it must also be considered that the terminal stem of
the molecule contains elements responsible for transcription initiation and termination.
The ascending arm of the terminal stem contains the Box A internal promoter for RNA
polymerase III, and the descending arm of the terminal stem contains the transcription
termination signal (25, 42, 55). There is likely a high degree of selective pressure to
maintain these sequences to allow for appropriate transcription of the VA RNA molecule.
Regardless, the fact remains that the miR-VA region of the VA RNA I molecule is highly
conserved and may therefore serve a related function in multiple strains of adenovirus.
 Our results demonstrate that adenovirus produces miRNAs, miR-VAs, which
enter into host RNA silencing pathways during the course of infection.  This provocative
finding suggests that these miRNAs may play important roles in viral pathogenesis.  Due
to their compact genome sizes, viruses typically only encode factors required for efficient
infection and replication.  Numerous examples of viral factors performing multiple,
disparate functions exist.  VA RNA may well represents another of these multivalent
factors, as it now appears to play a role in the RNA silencing pathway in addition to its
previously established role in blocking the PKR-induced interferon response.
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Finally, we additionally demonstrated that other structured viral or cellular RNAs
may be substrates for RNA silencing pathways (Fig. 3.11 & 3.12).  Our results indicating
that VA RNA II is diced in vitro correlates with our observation that small VA RNA II-
specific RNAs are detectable in infected cells by northern blot and microarray tiling
analysis.  While our attempts to identify a functional miR-VA2 capable of producing
RISC-mediated cleavage were unsuccessful, another study did demonstrate that VA RNA
II-specific small RNAs could cleave a target in vitro and regulate a target reporter gene in
cell culture (4). Further experiments to improve the sensitivity of our cleavage assay
should be performed, as well as studies to examine the potential function of VA RNA II-
specific small RNAs in infected cells.  While our dicing assay results from the other
structured viral and cellular RNAs (EBERs, Alu) are only preliminary, in vitro studies,
they do raise the possibility that production of small RNAs by mammalian viruses is a
common theme in virus infections.  To this end, numerous miRNAs produced from other
animal viruses have recently been described (22, 29, 54, 57, 146, 147, 171).
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CHAPTER IV:
ADENOVIRUS INFECTION DISRUPTS
MULTIPLE COMPONENTS OF HOST
RNA SILENCING PATHWAYS
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Introduction
The co-evolution of viruses with their hosts has led to a molecular arms race as
viruses seek to elude the host pathogen defense pathways and successfully infect and
propagate in the host.  There is a seemingly endless array of viral mechanisms deployed
for counteracting host defense measures.  There are also numerous examples of viruses
co-opting the use of a cellular pathway to aid in their viral replication.  Prior to the
discovery of RNA silencing pathways in the 1990s, the mammalian host defense against
viruses was believed to be comprised solely of a rapidly responding non-specific innate
immune defense system, followed by a specific protein-based adapted immune response.
However, recent discoveries of RNA-based forms of immunity in plants and insects
raised the possibility that similar mechanisms may exist in the mammalian host response
to viruses.
Our work, along with others, has demonstrated that during adenovirus infection,
the viral RNAs, VA RNA I & II, enter the host RNA silencing pathway and are processed
into authentic miRNAs (4, 6, 158).  This definition of “authenticity” is based on the
ability of the miRNA to regulate experimentally introduced target RNAs in a sequence
specific fashion.  However, this does little to define the importance of the miR-VAs to
the process of viral infection or the host response to infection.  We undertook
experiments to refine our understanding of miR-VA’s role in virus infection, as well as
the importance of host RNA silencing mechanisms in the context of a viral infection.
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Results
Inhibition of miR-VA does not affect viral growth
The demonstration that miRNAs are produced by adenovirus raises the obvious
question as to what their function is in the context of infection.  There have been a
plethora of recent studies, both computational and experimental, demonstrating the
presence of miRNAs in animal viruses (22, 29, 54, 57, 146, 147, 171).  For those
miRNAs that have been experimentally tested, a variety of different functions have been
found.  A miRNA produced from the Epstein-Barr virus is perfectly complementary to
the 3´UTR of the DNA polymerase gene transcribed on the opposite strand.  The miRNA
is able to perform site-specific cleavage of the polymerase transcript, which may
contribute to the establishment of a latency stage for the virus (147).  Similarly, a miRNA
produced by the simian virus, SV40, slices early gene RNAs which bear perfect
complementarity to the miRNA, thereby reducing expressing of viral T antigens, making
the infected cells less susceptible to immune control (171).  Since there are no viral
transcripts containing perfect target sites for miR-VA, we performed experiments to try
to ascertain the importance of miR-VA to the process of virus replication.
In order to test whether miR-VA affected replication of adenovirus, we utilized a
sequence-specific 2´oMe oligonucleotide inhibitor of miR-VA to block its function
during infection.  The use of 2´oMe oligonucleotides as potent inhibitors of siRNA and
miRNA-loaded RISC has been studied in variety of settings, including in vitro reactions,
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D. melanogaster embryos, cultured human cells, and C. elegans larvae (66, 104, 125).
We previously verified that a miR-VA specific 2´oMe inhibitor was able to block target
cleavage in in vitro reactions (Fig. 3.8). For this experiment, we additionally tested a
2´oMe inhibitor specific for the region of VA RNA II that microarray tiling and northern
blot analysis indicated also give rise to a viral miRNA.  Accordingly, we also performed
infections using the dl331 (∆VA I) virus, under the assumption that if there is a functional
miR-VA2, it would be easier to test for its function in the absence of VA RNA I.  We
further reasoned that since miR-VA was produced so quickly after infection (Fig. 3.5),
we should provide the 2´oMe inhibitors a priori in order to effectively block its function.
Therefore, we transfected HeLa cells with the 2´oMe inhibitors 12 hours prior to
infection with WT of dl331 virus. The supernatant and cell pellet were removed every 12
hours post infection for a total 48 hours, and titering assays were performed to determine
virus levels.  In our experiments, neither the 2´oMe specific for VA I or VA 2, or a
combination of both was able to affect the growth of the virus in relation to a control
inhibitor (2´oLuc) (Fig. 4.1).  In experiments using both the WT and dl331 virus, the
virus growth curves looked remarkably similar for all of the 2´oMe inhibitors used,
indicating that their presence did not influence virus replication.  While our experiment
produced negative results, we did have a measure for efficacy of the 2´oMe treatment.
Extra wells in the experiment were transfected with a 2´oMe inhibitor specific for the
cellular miRNA, let-7.  Bioinformatic predictions and in vitro experiments have shown
that let-7 regulates the human Dicer mRNA (71, 163). We performed western blot
analysis on these samples and saw that Dicer protein levels were elevated in the 2´-o-let-
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WT Ad-5
dl331 (∆VA1)
Fig 4.1: Inhibition of miR-VA does not affect viral replication.
HeLa cells were transfected with 20 nM of the specified 2 o´Me oligonucleotide 
inhibitors 12 hrs prior to infection with WT Ad-5 or dl331.  Lysates were collected 
and viral titer was determined at the indicated timepoints.
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7-treated cells relative to 2´-o-Luc-treated cells, indicating that our transfection protocol
worked (data not shown).  From these studies, it does not appear that miR-VA impacts
virus propagation in this cell culture setting.
miR-VA “A” is predicted to target Dicer mRNA
To date, two examples of miRNA produced from animal viruses have been found
to regulate viral transcripts bearing perfect complementarity (147, 171).  In the case of
miR-VA, this is unlikely, since there is no transcript produced antisense to the miR-VA
locus in the adenovirus genome and additionally, there are no other cis sequences within
the virus bearing perfect complementarity to the miR-VA seed sequence.  However, it is
still formally possible that miR-VA regulates expression of cellular genes.  Bioinformatic
algorithms have been developed to aid in the prediction of mRNA targets for miRNAs of
interest (37, 101).  We provided the sequences of miR-VA “g” and miR-VA "A" to the
developer of the TargetScan prediction tool and were provided with a series of putative
targets for the miRNAs.  However, a serious limitation of this approach was imposed by
the species-restricted tropism of adenovirus.  A key component of the target prediction
algorithm is conservation of the miRNA sequence and its putative target sequence across
several species (101). Conservation of these sequences implies selective pressure to
maintain those sites, underscoring their importance.  Because human adenoviruses only
infect humans, the algorithm cannot use the same cohort of species normally used in its
analysis for targets of a conserved miRNA.  Additionally, the algorithm did not provide a
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sufficient list of high scoring targets for miR-VA "g".  At the time this analysis was
performed, there had not been a single human miRNA identified that encoded a
guanosine at the 5´end.  Therefore, a bias against miRNAs with a 5´guanosine and
respective target sequences was built into the algorithm.  Since that time, there have been
49 human miRNAs found to encode a 5´guanosine from a listing of 474 total human
miRNA (~ 10%).  While the algorithm provided few targets for miR-VA "g", it generated
a large list of targets for miR-VA "A", including several high scoring putative targets
bearing multiple predicted sites of regulation.  Of the list, one of the top scoring potential
targets was the mRNA for human dicer.  The TargetScan algorithm predicted 4 potential
miR-VA "A" sites of regulation, with two sites residing in the coding region of the gene
and the other two in the 3´ UTR (Fig. 4.2).  All four of these sites maintain a high level of
pairing between the seed sequence of miR-VA and the target mRNA.
Dicer mRNA and protein levels decrease during adenovirus infection
To examine the potential effect of miR-VA on cellular Dicer levels, we first
investigated the levels of Dicer mRNA during adenovirus infection.  This was performed
using quantitative real-time PCR on reverse-transcribed cDNA derived from total RNA
in infected cells.    We found that infection of HeLa cells reduced by ~3-fold the steady
state abundance of Dicer mRNA (Fig. 4.3).  Interestingly, and reproducibly, we saw an
initial increase in Dicer mRNA levels after infection, peaking around 12 hours after
infection, prior to the levels of mRNA dropping dramatically.
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Mock
WT Ad-5
Fig. 4.3: Dicer mRNA levels are reduced during adenovirus infection.
Total RNA was collected from mock-infected or WT Ad-5-infected HeLa cells at the 
indicated times, was reverse transcribed, and was used for quantitative real-time PCR 
using primers to amplify Dicer  or  a housekeeping gene (GAPDH).  All data points for 
relative dicer mRNA levels are internally normalized to GAPDH mRNA levels.     
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Additionally, we found that Dicer protein levels also decreased over the course of
the infection (Fig. 4.4).  Again, we see Dicer protein levels initially rise, before rapidly
decreasing.  However, in this experiment we also observed that the level of Dicer protein
is decreasing in cells infected with the dl331 virus (Fig. 4.4).  Because this mutant does
not express VA RNA I, it appears that the downregulation is not directly linked to the
presence of VA RNA, and therefore, miR-VA "A".
miR-VA "A" does not directly regulate Dicer
We performed several additional assays which verified that miR-VA "A" does not
directly impact Dicer levels.  First, we set up an in vitro cleavage assay to determine if
the predicted miR-VA "A" target sites for Dicer mRNA could be cleaved by an siRNA
corresponding to the guide strand of miR-VA "A" in D. melanogaster extract.  For this
assay, we developed four new target RNAs similar to the perfectly complementary target
created for miR-VA "A" (Fig. 3.8).  Each of these targets contained the perfect
complement to one of the predicted miR-VA "A" target sites in Dicer mRNA (sites A-D,
Fig. 4.2).  These targets were incubated in fly extracts pre-loaded with siRNA
corresponding to miR-VA "A", a control siRNA (siLuc), a positive control siRNA
(siLin41), which cleaves a perfect-pairing site engineered into all targets, and an siRNA
corresponding to the predicted Dicer target site. (siDcrA-D) (Fig. 4.5 A).  As expected,
the siLin41 siRNA cleaved each target, while the siLuc did not cleave the target.
Importantly, none of the targets was cleaved by miR-VA "A" over the timecourse.
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12  24  36  48  60 12  24  36  48  60 12  24  36  48  60
WT Ad-5
dl331
Fig. 4.4: Dicer protein levels are reduced in adenovirus-infected cells.
Whole cell extracts were prepared from infected HeLa cells at the indicated 
timepoints.  Western blot analysis was performed using a monoclonal antibody 
for human Dicer (Clonegene) and œ-tubulin (Santa Cruz).  Data from the 
Western was quantitated (internally normalized to tubulin) and plotted.
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However, only one of the perfectly matched target site siRNAs (siDcrA) was able to
cleave its target.  Further studies are needed to verify that these siRNAs and targets
contain the appropriate sequences.  These targets were also incubated in infected HeLa
cell extracts, and no specific cleavage products for any of the targets were detected (Fig.
4.5 B).
Finally, in order to further examine if miR-VA has any role in regulating Dicer
mRNA or protein, we used siRNAs corresponding to the guide strand of miR-VA "g" or
miR-VA "A" to perform transfections in cultured human cells.  HeLa cells were
transfected with the siRNA and total RNA or protein was collected every 24 hours for 3
days.  The RNA samples were reverse transcribed and used for quantitative real-time
PCR analysis.  We saw that transfection of siVA "A" alone was unable to reduce the
level of Dicer mRNA (Fig. 4.6).  As expected, siVA "g" also did not regulate Dicer
mRNA levels, whereas the siRNA specific for Dicer (siDcr) was able to greatly
knockdown Dicer expression.  Similarly, when we looked at protein levels from another
set of transfections, we saw that the miR-VA-siRNAs were unable to downregulate Dicer
protein levels, while the siDcr did provide a significant reduction in Dicer protein (Fig.
4.7).
 Therefore, despite the in silico prediction that miR-VA "A" targets Dicer mRNA,
we find that miR-VA "A" is not solely responsible the observed decrease in Dicer mRNA
and protein levels in infected cells.  It has been demonstrated that typical mRNAs bear
multiple miRNA target sites for a heterogeneous population of miRNAs (101).  Indeed,
detection of miRNA regulation by a single miRNA in cell culture typically requires the
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Fig. 4.6: miR-VA alone does not regulate Dicer mRNA.
HeLa cells were transfected with the indicated siRNAs and total RNA was extracted 
every 24 hrs. for three days.  Reverse transcription and quantitative real-time PCR was 
performed to determine the level of dicer mRNA at each timepoint.  Each sample is inter-
nally normalizd to GAPDH mRNA then further normalized to the siLuc sample at each 
timepoint.
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Fig. 4.7: miR-VA alone does not regulate Dicer protein.
HeLa cells were transfected with the indicated siRNAs and whole cell extracts were 
prepared every 24 hrs. for three days.  Western blot analysis was performed using a 
monoclonal antibody for human Dicer (Clonegene) and a-tubulin (Santa Cruz).  Data 
from the Western was quantitated (internally normalized to tubulin) and plotted.  
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presence of 4 or more target sites to be generated in the 3´UTR of the gene of interest
(32). Therefore, it is still formally possible that miR-VA "A" plays a synergistic role with
other cellular miRNAs in the downregulation of Dicer mRNA/protein levels in infected
cells.  Perhaps there are cellular miRNAs expressed in response to adenovirus infection
which perform this collaborative action.  However, the demonstration that the dl331 virus
was able to induce downregulation of Dicer protein suggests that miR-VA “A” is not
essential for this downregulation (Fig. 4.4).
Dicer protein levels inversely correlate with the level of replication in infected cells
Since miR-VA "A" does not appear to specifically cause the observed reduction
in Dicer levels, there is likely another viral factor mediating this effect.  In the course of
our studies, we observed differential effects on Dicer protein levels depending upon the
particular virus and cell line used.  Specifically, we found that the dl331 (∆VA I) virus
did not cause a dramatic loss of Dicer protein levels in 293 cells.  A search of the VA
RNA literature reveals studies performed in the 1980s discussing this mutant virus
growth defect. Inhibition of PKR is the main activity described for VA RNA I and to a
lesser extent, VA RNA II (83, 159). The growth defect of dl331 in 293 cells has been
attributed to the inability of the virus to block PKR activation and the subsequent
shutdown of host translation.  This growth defect appears to be proportional to the level
of PKR in the infected cell, as the virus has a greater than 1 log growth defect in 293
cells, which express high levels of PKR, but grows similar to WT virus in cells with low
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levels of PKR, such as GM2767A cells (159).   We performed a growth curve analysis
for WT and dl331 viruses in 293 and HeLa cells (Fig. 4.8).  As predicted, dl331 grew
poorly in relation to the WT virus, as there was nearly a 2 log difference in titer at 24
hours post infection.  Contrastingly, there was only a modest difference in titer for the
viruses when the infections were performed in HeLa cells.
When we performed western blot analysis to examine Dicer in infected 293 and
HeLa cells, we saw that Dicer protein levels during infection also inversely correlate with
the replication of virus (Fig. 4.9).  In HeLa cells, where the dl331 virus grows at nearly
the same level as the WT virus, Dicer protein levels were decreased for both viruses.  In
contrast, when the same analysis is performed in 293 cells, we observed that the poorly
growing dl331 virus does not cause the same diminution of Dicer as WT Ad-5.
Therefore, there is likely another viral factor produced during active infection that causes
the observed effect.  This downregulation of Dicer is unlikely to be part of a large scale
downregulation of host mRNA and protein expression, since several microarray studies
have indicated that surprisingly few cellular genes (~100) are significantly regulated by
adenovirus at 24 hours post infection (34, 50, 208).
Dicer protein levels do not affect virus replication
Since we reproducibly observed that dicer levels were not reduced in 293 cells
infected with dl331 virus, we asked whether Dicer was partially responsible for the
observed attenuation of virus replication.  The described growth defect of the dl331 virus
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293
HeLa
Fig 4.8: dl331 (∆VA1) virus has a growth defect in 293 cells.
HeLa or 293 cells were  infected with WT Ad-5 or dl331.  Lysates were collected 
and virus titers were determined at the indicated timepoints.
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HeLa
293
Fig. 4.9: Adenovirus-induced downregulation of Dicer inversely correlates with 
replication.
Whole cell extracts were prepared from mock-infected or adenovirus-infected HeLa or 293 
cells at the indicated timepoints.  Western blot analysis for Dicer protein levels was 
performed.  Each sample is internally normalized to a-tubulin, and samples were then 
normalized to mock infected sample at each timepoint.
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in 293 cells has been solely attributed to the high levels of PKR in these cells (159).
However, we have also observed that 293 cells express higher levels of Dicer protein and
have more dicing activity than other human cell lines examined (Fig. 4.10).
Unfortunately, we were unable to derive a quantitative measure of Dicer activity in 293
cells in relation to other human cell lines because we were unable to detect dicing in any
cell line other than 293 cells.  We reasoned that perhaps the compromised ability of the
dl331 virus to grow in 293 cells was also partially due to the higher level of Dicer protein
in these cells.  To test this, we employed two related approaches.  The first was to reduce
levels of Dicer protein in cells prior to infection via siRNA knockdown.  In the second
approach, we increased levels of Dicer prior to infection by expression of a plasmid
encoding the human Dicer cDNA.  If Dicer plays a role in limiting adenovirus
replication, then we would expect that reduction of Dicer levels would make 293 cells
more permissive to infection.  Conversely, overexpression of Dicer in a cell line
containing lower levels of endogenous Dicer expression (HeLa cells) would be expected
to limit replication of adenovirus.
We saw no indication that the level of Dicer protein was of crucial importance to
the efficiency of viral infection and replication.  When siRNAs were used to knockdown
Dicer levels prior to infection, we saw no difference in the growth of either the wild type
or dl331 virus in HeLa or, more importantly, 293 cells (Fig. 4.11). Similarly, we saw no
effect on virus growth when the converse experiment was performed.  When Dicer was
expressed exogenously in cells prior to infection, we did not see any impact on the
growth of either the wild type or mutant virus in 293 or, more importantly, HeLa cells
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Fig. 4.10:  293 cells contains higher levels of dicing activity than other mammalian 
cell lines.
RNAi-competent extracts were prepared from the indicated mammalian cell lines.  
Standard in vitro dicing reactions were performed using a 500 bp dsRNA target.  RNA 
was electrophoresed on a 15% polyacrylamide gel.
Time (hrs.)
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Fig 4.11: Knockdown of cellular Dicer protein does not alter virus replication.
HeLa or 293 cells were transfected with a control siRNA (siLuc) or an siRNA specific for 
human Dicer (siDcr).  Twelve hours later, cells were infected with WT Ad-5 or dl331 virus.  
Lysates were collected and virus titers were determined at the indicated timepoints.
HeLa
293
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(Fig. 4.12).  We confirmed the knockdown and overexpression of Dicer protein in these
respective studies by performing western blot analysis for Dicer protein (data not shown).
These experiments indicate that Dicer protein does not appear to regulate growth of
adenovirus in these settings.
Examining the impact of adenovirus infection on cellular miRNA biogenesis
We and others have provided data that adenovirus utilizes several mechanisms to
counteract Dicer function, including the reduction in cellular Dicer levels as well as the
production of RNA molecules, VA RNA, that can compete with endogenous pre-miRNA
for processing by Dicer and export by Exportin-5 (4, 111).  These viral activities have the
potential to greatly impact the endogenous miRNA pathway in infected cells.  Because
Dicer levels and function are being impaired, a prediction would be that cellular pre-
miRNAs are not processed efficiently to mature miRNAs during adenovirus infection.
To test this, we performed northern blot analysis to compare the levels of specific pre-
miRNAs in mock-infected cells and adenovirus-infected cells.  If adenovirus is affecting
the ability of Dicer to process cellular miRNAs, then pre-miRNA levels would be
expected to rise during infection.  After several attempts using DNA and RNA-based
probes for several different miRNAs, we were finally able to detect pre-miRNA species
using an antisense probe containing locked nucleic acid nucleotides (LNA), which was
specific for miR-17-5p (85, 180).  These modified nucleotide probes have very high
thermal stability when hybridized with DNA or RNA sequences (85, 145).  The northern
104
Fig 4.12: Dicer overexpression does not alter viral replication.
HeLa or 293 cells were transfected with a control plasmid (pCDNA) or a plasmid 
overexpressing human Dicer protein (pDcr).  Cells were infected with WT Ad-5 or 
dl331 virus 12 hours later.  Lysates were collected and virus titers were determined 
at the indicated timepoints.
HeLa
293
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blot data for miR-17-5p indicated that there was not an increase in pre-miR-17-5p in
either HeLa or 293 cells (Fig. 4.13).  In fact, the level of the precursor appears to drop to
nearly undetectable levels in infected cells.  In analyzing the mature miRNA, we observe
that after an initial modest increase in miR-17-5p levels in WT-infected HeLa cells, there
was a marked decrease in the level of mature miRNA (Fig. 4.13).  However, the same
does not hold true in 293 cells, as there was no initial increase in mature miRNA; rather,
there appears to be an increase of the miR-17-5p at later points of the infection, although
analysis of the tRNA loading control indicates that there may have been unequal loading
in both the WT and dl331 72 hour samples.  This analysis only includes a single pre-
miRNA, so major conclusions cannot be drawn from this experiment.  Additional probes
to other miRNAs, designed with the LNA modifications will be crucial in helping to
accurately detect pre-miRNAs in future experiments.  Also, the control samples on this
blot indicate that downregulation of Dicer appears to produce only subtle differences in
pre-miRNA levels at early timepoints.  These control wells contain RNA from HeLa cells
transfected with siRNAs specific for Dicer mRNA (siDcr) or a non-specific control
(siLuc).  Efficient knockdown of Dicer levels was obtained with these transfections
(confirmed by western blot for Dicer protein), yet we only observe a modest effect on the
level of pre-miRNA and miRNA at 24 hours post-transfection (HeLa blot).  There is a
7% increase in pre-miR-17-5p and a 40% decrease in mature miRNA at 24 hours after
this efficient transfection.  In contrast, samples taken from 48 hours post transfection lead
to a 40% increase in the level of pre-miRNA and a 70% decrease in the mature miRNA
(Fig. 4.13, 293 blot).  It is possible that in our experimental setting, where virus infection
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kills the cells rapidly (within 48-72 hours), there is not adequate time to observe potent
effects on cellular miRNA biogenesis caused by disruption of cellular Dicer.
To further test for cellular miRNA function during infection, we performed in
vitro target cleavage assays to examine the levels of a functional miRNA in the infected
cells.  We prepared a target RNA bearing a region of perfect complementarity for the
cellular miRNA, let-7a (61).  RISC-mediated target cleavage reactions were performed in
extracts prepared from mock-infected or adenovirus-infected cells from various
timepoints post infection.  Therefore, this assay examines the levels of endogenous,
RISC-associated let-7a in the infected cells.  We also performed cell counts prior to
preparation of the extracts, since adenovirus infection will influence the number of cells
due to viral pathogenesis.  A method for determining the concentration of a RISC-
associated miRNA has been described for this in vitro target cleavage assay (66).  In the
assay, increasing amounts of a specific 2´oMe inhibitor for the miRNA are included in
target cleavage reactions to inhibit target cleavage (as performed in Fig. 3.8).  Since
2´oMe inhibitors act as stoichiometric inhibitors of RISC cleavage, the amount of 2´oMe
required for half maximal inhibition of target cleavage (IC50) is directly proportional to
the concentration of RISC (66).    Using this analysis, we determined the [let-7-RISC] in
each extract and found that the level of functional, RISC-associated let-7 was slightly
increased during infection (Table 4.1). These results indicate that the viral manipulation
of Dicer levels and function in infected cells does not lead to dramatic decreases in the
level of RISC-associated miRNA.
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Adenovirus infection leads to altered expression of a small subset of miRNAs
The previous experiments aimed at determining the effect adenovirus-induced
perturbations of Dicer levels and functions has on infected cells examined only two
cellular miRNAs for their expression and activity (Fig. 4.13 & Table 4.1).  We also
desired to gain a global perspective of how miRNA levels were changing in response to
adenovirus.  To examine the cellular pool of miRNAs during infection, we performed a
miRNA microarray experiment.  In this experiment, RNA from mock-infected and WT
Ad-5-infected cells was hybridized to a microarray containing all known human miRNA
and miRNA* sequences identified at that time (LC Sciences, Houston, TX).  We chose to
use RNA from 24 hours post infection, a time at which infected cells are showing
obvious signs of cytopathology, but prior to dramatic changes in cell morphology and
detachment from the tissue culture plate.  To date, there are no published studies
examining the expression of all miRNAs in the context of infection.  A literature search
produced only one similar study, where an infectious clone of HIV was used to transfect
cells prior to array detection of miRNAs (198).
Our miRNA analysis indicated that at 24 hours post infection, there are relatively
few changes in miRNA gene expression between the mock-infected and adenovirus-
infected samples (Fig. 4.14).  Most miRNAs in this analysis had comparable expression
in the samples, as indicated by the linear trend of the data points.  We considered all
miRNA genes whose expression changed (increased or decreased) by at least 1.5 fold as
significant.  By these criteria, only 19 miRNAs or miRNA*s were differentially
110
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regulated.  This result is in accordance with our previous limited analysis of miRNAs in
infected cells, where we did not detect appreciable changes in miRNA level or activity
(Fig. 4.13 and Table 4.1).  On a whole, it appears that the accumulation of miRNAs is not
grossly affected 24 hours after infection.  However, there are 19 miRNA or miRNA*
sequences that are significantly altered in infected cells (Fig. 4.15 & Fig. 4.16).  Perhaps
these miRNAs and miRNA*s represent a subset of the miRNA population that helps
establish an environment that is permissive for infection and replication.  Alternatively,
these miRNAs may represent a response from the host to modulate genes involved in the
immune response.
Interestingly, three of the five miRNAs upregulated by adenovirus infection, miR-
17-5p, miR-19a, and miR-19b have previously been experimentally validated as key
regulators of genes involved in cell cycle progression (138).  These miRNAs exist in a
miRNA polycistron (miR-17-92) of 7 total miRNAs, whose expression is misregulated in
certain tumors (23). These so called “oncomirs” have been shown to regulate expression
of E2F1, and expression of the miRNA locus itself is regulated by the c-myc transcription
factor (138).
There are also many other interesting potential cellular mRNA targets for the
subset of misregulated miRNAs.  Unlike our previous attempts to define a cellular target
for miR-VA, these predictions will prove much more reliable, as conservation of the
cellular miRNA and its perspective targets across a panel of species can be utilized in the
algorithm.  Additionally, recent refinements to the target prediction algorithm have been
made to more accurately predict target genes (72, 100).  A listing of the misregulated
112
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miRNAs with some of their predicted cellular targets is provided in Table 4.2 and Table
4.3.  These lists include only high scoring predictions, and they contain some intriguing
potential regulators of immune defense, cell cycle control, and even RNA silencing
components.  Additionally, we observed that one of the miRNAs downregulated during
infection, miR-28, bears prefect complementarity in its seed sequence to the 3´ end of
miR-VA "A" (Table 4.2).  What significance this complementarity has is unknown, but
we do find this to be a very interesting observation to further pursue.
This microarray analysis provided us with a wealth of information to use for
follow up studies.  Obviously, all of these potentially misregulated miRNAs will need to
be validated with further northern blot and microarray analysis.  However, these
preliminary finding have the exciting potential to uncover new aspects of adenovirus
infection, as well as the host response to virus.
Infection by another DNA virus, human cytomegalovirus (HCMV), produces a pattern of
miRNA regulation distinct from that of adenovirus
We also performed miRNA microarray analysis on RNA from cells infected with
another unrelated DNA virus, human cytomegalovirus (HCMV).  HCMV is a member of
the Herpesvirus family, which contains some of the largest and most complex viruses.  Of
this family of viruses, CMV is the largest member, with a genome size of 230 kb.
Accordingly, CMV encodes a wealth of viral gene products that subvert the host cell into
a machine for virus production.  Numerous immunomodulatory activities have been
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described for this virus.  We performed miRNA microarray analysis for HCMV infection
of HEL cells, harvesting RNA at 48 hours post infection.  Once again, we used specific
probes to detect all known miRNA and miRNA* sequences at the time of the array.
Similar to the adenovirus array, we saw that the majority of cellular miRNAs are
unaffected by virus infection at this timepoint, as most miRNAs in a space plot of mock
versus infected samples fell along a linear trace (Fig. 4.17).  Not surprisingly, a higher
percentage of miRNAs had significant changes in their expression than was seen with the
adenovirus array (Fig. 4.18a/b & Fig. 4.19).   Most of these miRNAs with altered
expression levels were downregulated in response to infection (Fig. 4.18a/b).
Interestingly, only one miRNA was similarly misregulated in both HCMV and
adenovirus infection.  This miRNA, miR-181b, was downregulated during both
infections, raising the possibility that this miRNA regulates factors that are important for
a host response to infection.  Also, unlike the upregulation of oncomirs in adenovirus
infection, we observed that no miRNAs previously associated with cancer signatures
were significantly upregulated in response to CMV (187). However, we did observe that
several members of miRNA families displayed coordinated downregulation in response
to virus (Table 4.4).  Unlike the miR-17-92 polycistron, many of the miRNAs in miRNA
gene families are not in close proximity.  In fact, many reside on different chromosomes.
Therefore, coordinated regulation of these miRNAs would underscore the importance of
these particular gene families in the context of infection.
An attractive hypothesis from these microarray analyses is that different viruses
induce different miRNA signatures in their host cells, and that these patterns of miRNA
118
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miR-181
miR-148
miR-221
miR-154
miR-181a, miR-181b, 
miR-181c, miR-181d
miR-148b, miR-152
miR-221, miR-222
miR-154, miR-409-5p, 
miR-409-3p, miR-410, 
miR-487b, miR-494
miRNA 
Family
miRNA Family 
Members 
Coordinately 
Regulated On Array
Table 4.4: miRNA gene families misregulated in response to HCMV infection.
Global miRNA microarray analysis was performed on RNA from mock-infeced or 
HCMV-infected HEL cells. Family members that were similarly downregulated in response 
to HCMV infection are shown.
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expression are important regulators of genes involved in the process of infection.  We are
currently verifying and extending our microarray analysis by comparing miRNA profiles
from adenovirus and CMV infections at similar timepoints in the same cell line (HEL).
Our hope is that these results will shed light on key miRNAs involved in host response to
infections, as well as distinct miRNAs that define specific viral infections.
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Discussion
Defining a role for miR-VA
Our work has demonstrated that adenovirus produces a miRNA species, miR-VA,
from the VA RNA I locus during the course of infection.  We took several different
approaches in an attempt to ascertain the importance and function of this miRNA.  First,
we utilized a specific 2´oMe antisense inhibitor of miR-VA to block the function of miR-
VA in infected cells.  When the 2´oMe oligonucleotide was introduced into cells 12 hours
prior to infection, it had virtually no effect on virus replication, as growth curves for the
viruses in cells treated with the specific inhibitor were identical to those transfected with
a control 2´oMe oligonucleotide (Fig. 4.1).  These results are in contrast to another study,
which showed that 2´oMe inhibition of the miR-VA region produced a modest reduction
in virus accumulation (6).  Several important differences exist in the protocols used in
this study versus ours, including the cell line used, size of the 2´oMe inhibitor,
concentration of inhibitor, and method of virus collection.  Our study used HeLa cells, a
20 nM final concentration of a 2´oMe inhibitor antisense to the 22 nucleotide miR-VA
“A”, and collection of supernatant and cellular fractions for titering.  The other group
utilized 293 cells, a 100 nM concentration of 2´oMe inhibitor covering the miR-VA "A"
sequence plus an additional 8 nucleotides upstream of this sequence, and a collection of
supernatant for titering.  Any or all of these differences in the protocol could contribute to
the discrepancies between the experiments.  Therefore, it would be beneficial to repeat
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the experiment using the same conditions used in their study.  However, from our initial
analysis, it does not appear that miR-VA affects virus replication in this cell culture
setting.
We also attempted to ascertain the function the miR-VA by identifying cellular
mRNA targets that would be subject to miR-VA regulation.  The TargetScan algorithm
produced a high scoring match for miR-VA "A" to regulate cellular Dicer (Fig. 4.2).
However, a series of tests for the ability of miR-VA to regulate these target sites in vitro
and in cell culture failed to support the bioinformatics prediction (Figs. 4.5- 4.7).  In all
likelihood, the incorrect target prediction suffered from the fact that one of its most
important parameters for significance, conservation of miRNA and target sequence
across multiple species, had to be removed for this analysis.  This was due to the fact that
the human adenovirus exhibits species-specific tropism.
These experiments failed to uncover functional significance for miR-VA in our
cell culture infection model.  However, it is possible that the miRNA is not necessary for
the virus in this artificial infection setting.  To date, the examples of viral miRNAs from
animal viruses appear to play important roles for the virus in the context of a host
organism.  The EBV-encoded miRNAs are alternately expressed in various stages of the
virus life cycle, and look to be important factors in the establishment and maintenance of
latency (147).  Similarly, a miRNA produced from the herpes simplex virus latency-
associated transcript (LAT) regulates apoptosis in infected cells, contributing to the
persistence of the virus (57).  The SV40-encoded miRNAs regulate viral transcript
expression, thus limiting the level of T antigen produced by the virus in a mechanism
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which renders the infected cells less immunogenic (171).  All of these examples of viral
miRNAs involve the regulation of factors involved in persistence and/or latency for the
virus in a host.  Therefore, it is possible that the role of miR-VA may not be properly
studied in a cell culture setting.  There is precedence for adenovirus to establish a
persistent state of infection, as studies have described the isolation of adenovirus from
cultured adenoid and lymphoid tissue of human subjects (181). Studies also demonstrated
that the virus grew very slowly in infections of human lymphocytes, which may mimic
the persistent state of infection (87).   Perhaps it is in settings such as this that miR-VA
will display its importance and function.
Adenovirus affects Dicer at multiple levels
Our studies to determine if miR-VA "A" regulated cellular Dicer levels initially
led to the confusing result that both Dicer mRNA and protein are reduced during the
course of adenovirus infection, though not through the direct action of miR-VA "A"
(Figs. 4.3 & 4.4).  This does not appear to be due to a global effect on host transcription,
as data from several microarrays indicates that wholesale changes in gene expression do
not occur during virus infection.  Rather, at 20 hours post infection only ~100 cellular
genes are significantly modulated in their expression (34, 50).  We noticed in both qRT-
PCR and western blot analysis that prior to the decrease in the levels of Dicer, there was
an initial increase at ~12 hours post infection.  This trend correlates well with the
expression pattern seen for a variety of immunomodulatory genes initially upregulated by
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adenovirus infection (50). This is suggestive that perhaps Dicer itself is a component of
the host immune response, as it is being targeted for inhibition by the virus, and its
expression patterns are similar to those seen for other immune defense genes.
 Our analysis of adenovirus infections in different cell lines indicated that the
observed reduction in Dicer levels inversely correlated with virus replication (Figs. 4.8 &
4.9).  In 293 cells, where the dl331 virus displays a growth defect, we saw that Dicer
levels were not compromised.  In contrast, the dl331 virus induced a reduction in Dicer
protein levels in HeLa cells, where the virus replicates at similar levels to WT Ad-5.  It is
likely that a viral gene product expressed at high levels in the setting of active virus
replication is responsible for the observed effect on Dicer.  Experiments using mutant
virus deleted for various adenovirus genes would be useful in helping to determine which
gene product causes this effect.  Likely candidates would be the viral E3 gene, which
performs a variety of immunomodulatory functions for the virus, or the E1A protein,
which is responsible for the activation and repression of a wide assortment of host genes
(165).
Interestingly, a published study reports that VA RNA suppresses the RNA
silencing response, because extracts from 293 cells infected with WT virus are far less
efficient at dicing a dsRNA substrate in in vitro reactions than extracts from dl331-
infected 293 cells (4). However, our data showing Dicer protein levels decreasing in cells
undergoing high levels of replication indicates that the effect described in this study may
actually be due to low levels of Dicer in the WT extract in relation to the dl331 extract.
Our testing of this hypothesis has been compromised by the fact that we are currently
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unable to detect in vitro dicing activity in extracts from any cell line other than 293 cells,
which appear to have higher levels of endogenous Dicer activity than the other human
cell lines examined (Fig. 4.10).
Finally, we tested the effect of the level of Dicer protein in infected cells on virus
propagation.  This was initiated by the observation that dl331 virus has a growth defect in
293 cells, which in addition to expressing higher levels of PKR than HeLa cells, also
contain higher levels of Dicer activity.  We tested the role of Dicer during infection in
these cells by either knocking down expression of Dicer with siRNAs (Fig. 4.11), or
overexpressing Dicer cDNA in cells prior to infection (Fig. 4.12).  We observed that
neither pre-treatment of cells to distort Dicer levels made an appreciable change in the
level of virus produced in the cells.  Again, during this rapid cell culture model of
infection there may not be enough time for the secondary effects of Dicer inhibition or
overexpression to be realized.
Assessing the impact of adenovirus on the host miRNA pathway
The accumulating data suggesting that adenovirus targets human Dicer for
regulation by several methods indicates that this molecule is an important host cell
regulator in the context of infection (4, 111).  A prediction from the studies would be that
miRNA biogenesis would be affected in infected cells since Dicer function is impaired.
We undertook several approaches to address this prediction.  Our initial studies focuses
on several individual miRNAs.  If Dicer function is impaired in cells, then we would
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expect to see an increase in the levels of pre-miRNAs and a concurrent decrease in the
levels of mature miRNAs.  We were initially unable to reliably detect human pre-
miRNAs using DNA or RNA-based probes.  However, we were successful in detecting
miR-17-5p using an LNA probe (Fig. 4.13).  Analysis of the pre-miR-17-5p did not
reveal an increase in the precursor during infection.  Instead, pre-miRNA levels appeared
to decrease during adenovirus infection.  We also did not observe a dramatic change in
mature miRNA levels during infection.  However, since this is only an analysis of a
single miRNA species, we cannot make any broad conclusions about impact on miRNA
biogenesis.  A RISC-mediated target cleavage assay was next used to measure the level
of endogenous let-7 activity in infected cells as well (Table 4.1).  The measured
concentration of let-7 in HeLa cell extract was in agreement with a previous study (65).
We did not detect a significant change in the level of let-7-mediated target cleavage in
infected cells.  These results from a limited sampling of cellular miRNAs suggest that the
cell culture model of infection for adenovirus may not produce large-scale perturbations
of cellular miRNA biogenesis, despite the observed effects on Dicer.  Although it has not
been properly tested, it is believed that miRNA-RISC complexes are very stable, with a
half-life that could be on the order of days to weeks (52).   Therefore, the impact on
RISC-associated miRNAs may not be fully realized at the observed timepoints in these
infection studies.
We performed a more comprehensive analysis of the cellular miRNA pool in the
face of infection by utilizing microarray technology to detect all known miRNAs and
miRNA*s.  In confirmation of the northern blot analysis and let-7-RISC activity assay,
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we saw that most cellular miRNAs did not change their expression significantly at 24
hours post infection (Fig. 4.17).  However, we observed a small subset of miRNAs whose
expression was misregulated during infection (Figs. 4.15 & 4.16).  These miRNAs may
prove to be important components in the establishment of an environment conducive to
adenovirus infection.  Or, alternatively, they may represent an attempt by the host cell to
regulate specific genes as a defense mechanism during infection.  Intriguingly, three of
the five miRNAs specifically upregulated during adenovirus infection belong to the miR-
17-92 oncogenic cluster.  Adenovirus is characterized as a small DNA tumor virus, as
selected strains of adenovirus can induce tumors in rodents (175).  Additionally,
adenoviruses transform cultured cells by the action of the viral oncogenes, E1A and E1B
(33, 49, 164).  Therefore, upregulation of these specific miRNAs fits into the
transforming, oncogenic profile of adenovirus.  Additional experiments need to be
performed to determine the significance of these miRNAs during adenovirus infection.
Analysis of miRNA expression during HCMV infection revealed that, like
adenovirus, the majority of host miRNAs were not significantly altered during infection
(Figs. 4.17- 4.19).  This larger, more complex DNA virus altered the expression of more
miRNAs than adenovirus, and there was surprisingly little overlap in those miRNAs and
miRNA*s that were misregulated.  Only miR-181b, miR-34c*, and miR-135b* were
coordinately regulated in adenovirus and HCMV infection.  If considerable overlap
occurred in the characterization of miRNA upregulated or downregulated in response to
both viruses, if might be concluded that those miRNAs regulated host defense factors.
However, based on our results, it appears that viruses may induce specific miRNA
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signatures.  It will be interesting to perform similar experiments in a variety of cell lines
to determine if these miRNA signatures persist.  If so, then these patterns of regulation
will provide important new clues about genes and pathways involved in virus infection.
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CHAPTER V:
DISCUSSION
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A. dsRNA and the host response to virus
Much like the non-specific mammalian immune response to dsRNA, the basic
principle underlying the RNAi silencing mechanism observed in invertebrate and plant
species is the general recognition of dsRNA as “foreign” material that must be dealt with
rapidly.  This cellular reaction likely stems from a universal association of dsRNA
species with viral pathogens, since viral dsRNA species are spuriously produced during
genome replication and bi-directional transcription activities.  Therefore, viruses must
find ways to circumvent this molecular bias against their dsRNA intermediates if they are
to successfully establish infection of the host cell.  To this end, numerous examples of
inhibitors from mammalian viruses have been identified which perturb the actions of the
innate dsRNA sensing molecules, such as PKR, 2-5A, RIG-I, and the TLRs (45, 76, 119,
120, 132, 152, 185).  A similar story has emerged in plants and invertebrates, where it
appears that RNA silencing pathways constitute the major anti-viral response.   In
response to this host defense system, inhibitors of various RNA silencing mechanisms
have been detected in a wide range of insect and plant viruses (186).
The relationship between a virus and its host is like that of chess match, with each
combatant strategically attempting to attack its opponent, and at the same time maintain
an impenetrable defense.  For nearly every host defense mechanism, there is a counter
defense system implemented by the virus.  Classic examples of this phenomenon include
the multiple counter mechanisms that HCMV has developed to defend against multiple
stages of MHC class presentation of viral antigen, and the multiple mechanisms utilized
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by poxviruses to prevent interferon activation (133, 162).  Adenoviruses similarly utilize
both E1A-mediated repression of interferon response genes and VA RNA inhibition of
PKR to abrogate the cellular interferon response (58, 149, 165).  The underlying
implication is that the more essential and powerful an immune response against a virus,
the more the virus will need to adapt ways to circumvent the response(s).   Using this line
of thinking and considering the established precedence of virally-encoded suppressors of
RNA silencing in plant and insect viruses, the hypothesis can be made that if RNA
silencing is involved in the immune response to mammalian viruses, then mammalian
viruses will correspondingly encode inhibitors of RNA silencing.  However, in
contradiction to this idea is the observation that some mammalian viruses encode
miRNAs, which require RNA silencing activity for their function.  This would imply that
mammalian viruses would not desire to subvert the host silencing pathways.
The work presented in this dissertation explores the relationship between the host
RNA silencing response and mammalian viruses, using adenovirus as a model virus.  Our
data as well as others suggests that the relationship between mammalian viruses and
RNA silencing is more complex than what is seen in plants and insects.  From our own
work, we observe that adenovirus encodes miRNAs, yet infection by adenovirus also
leads to a dramatic decrease in cellular Dicer levels.  Reports in the literature have
detailed examples of RNA silencing suppressors from mammalian viruses, as well as
virally-encoded miRNAs.   We will explore each of these aspects separately.
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Mammalian viruses encode suppressors of RNA silencing
Viruses are extremely efficient obligate parasites of host cells, as they maintain
their coding information in compact genomes.  Because of this, viruses do not encode
factors that are non-essential to their replication and fitness in some cellular context.
Viral genes that directly inhibit the function of a cellular gene product or pathway
provide a strong indication that the inhibited host factor or pathway would normally serve
to limit the infection of the virus.  Therefore, the presence of virally encoded inhibitors of
RNA silencing would imply that silencing pathways play a role in defense against the
virus.  In support of this idea, suppressors of RNA silencing have been identified in
mammalian viruses. Studies using the E3L and NS1 dsRNA-binding proteins from
vaccinia virus and influenza virus, respectively, demonstrated that these proteins could
suppress anti-viral silencing mechanisms in plants and insect cells (21, 30, 103).  These
results do not point directly to a similar role in mammalian cells, since the experiments
were performed in other systems.  Indeed, this observed inhibition could be non-specific
or not relevant to an infection in a mammalian cell where the primary role of these
proteins is to block PKR activation.  However, the presence of PKR and the IFN response
in mammalian cells preclude the obvious experiment of performing analogous studies in
mammalian cells.  A more appropriate study provided two pieces of data indicating that
RNA silencing responses were relevant to a host response to virus. It was demonstrated
that a cellular miRNA was able to restrict the growth of primate foamy virus (PFV) in
human cells.  The virus was found to have a complementary site to the endogenous miR-
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32 that is present in all viral transcripts.  The virus was also found to encode an RNA
silencing suppressor, allowing the virus to replicate in cells expressing miR-32.  The
suppressor protein, Tas, was also shown to inhibit silencing in mammalian cells as well
as plant cells (91).  These findings strongly suggested that RNA silencing is involved in a
host response to virus.
Our work, along with others, has demonstrated that adenovirus uses multiple
mechanisms to perturb Dicer expression and function.  We find that following infection,
an early increase in Dicer mRNA and protein levels is followed by a dramatic decrease
(Fig. 4.3 & 4.4).  This type of regulation is similar to what is seen for immune mediators
in response to cytopathic adenovirus infection (50).  Others have demonstrated that VA
RNA can act as a suppressor of pre-miRNA and dsRNA processing (4, 111).  The fact
that the virus employs multiple mechanisms to counteract the expression and function of
Dicer implies that this protein plays a role in host defense against the virus. In our hands,
artificially misregulating Dicer expression prior to adenovirus infection did not affect the
rates of virus replication (Fig. 4.11 & Fig. 4.12).  This result implies that an RNAi-like
response against viral dsRNA generated during infection is not a major determinant of
the ability of the virus to grow in the 293 or HeLa cell settings.  If viral siRNAs produced
from viral dsRNA actively worked to limit virus transcription, then we would have
expected to see an effect on virus replication when Dicer was overexpressed or repressed
prior to infection.  It is also formally possible that the MOI of virus used in these studies
(MOI=3) and the subsequent rate of viral replication was too high for us to see an effect
of Dicer misregulation.  A lower MOI or a cell culture setting allowing for slower
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replication of the virus may provide evidence of a Dicer-related effect on virus
replication.
Taken as a whole, the results of our work and others, indicates that RNA silencing
can impact the course of mammalian virus infection.  However, at this point there is not
enough evidence to suggest that RNA silencing is responsible for a general anti-viral role
against mammalian viruses.  Further experiments will be needed to test this theory.  For
our experiments, it would be valuable to establish an adenovirus infection setting that
more closely approximates what occurs in vivo.   Additional studies of mammalian
viruses should also be performed to try to identify an anti-viral role for RNA silencing.
Most plant viruses are RNA viruses, and therefore, most examples of plant virus-encoded
silencing suppressors derive from RNA viruses. As such, it would be advantageous to
look for evidence of silencing inhibitors in rapidly replicating RNA viruses. Further
studies of DNA viruses should include vaccinia virus, since the E3L protein has been
demonstrated to act as silencing suppressors in other systems and because the large
genome of poxviruses encodes numerous immunomodulatory genes.  The biggest
obstacle to studying the effects of RNAi in mammalian cells is the presence of PKR.
However, murine knockout PKR cells exist (167).  It would be informative to perform
experiments similar to our Dicer knockdown and overexpression studies in these cells
and examine the effect on the growth of various viruses.  We are unable to perform these
studies with adenovirus type-5, since the virus is tropic for humans, not rodents.
Similarly, other RNA silencing proteins, such as Ago-2 can be misregulated prior to
infection in this system.  However, a potential drawback to these studies is that it may be
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difficult to achieve high levels of transfection efficiency in these cells.  However, these
experiments have the potential to shed light on an anti-viral role for RNA silencing in
mammals.
Mammalian viruses encode miRNAs
Just as the demonstration that viral suppressors of RNA silencing imply a role for
those pathways in host defense, the presence of viral miRNAs in mammalian viruses
implies that viruses may be dependent of RNA silencing for viral fitness. Several
mammalian viruses have been shown to encode miRNAs through both experimental and
computational methods (22, 29, 54, 57, 146, 147, 171).  All of these miRNAs derive from
DNA viruses, which typically have larger genomes and encode more genes than RNA
viruses.  Additionally, a cellular miRNA that appears to assist replication of hepatitis C
virus in liver cells has been described (73). Our own studies of adenovirus VA RNA led
to the identification of previously unidentified miRNAs, miR-VAs, encoded within VA
RNA genes.  Other groups have described these miRNAs as well (6, 158).  We
demonstrated that these miRNAs are loaded into Ago-2 RISC complexes and could
perform cleavage of a target RNA, providing evidence that these are authentic miRNAs.
The identification of viral miRNAs and demonstration that they contribute to viral fitness
in some settings provides compelling evidence that mammalian viruses utilize and in
some instances, require host RNA silencing pathways.
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  At this point, the validated targets of viral miRNAs have been involved in the
development of a persistent or latent state of infection.  The EBV miR-BART2 has
perfect complementarity to the DNA polymerase gene, BALF5.  The slicing of this viral
transcript by miR-BART is thought to be an important autoregualtory function of the
virus as it establishes latency (147).  The SV40 virus miRNAs are thought to help the
virus induce a persistent state of infection by slicing early mRNAs bearing perfect
complementarity, thus reducing the level of immunogenic T antigen on the cell surface
and making the cells less susceptible to attack by cytotoxic T cells (171).  HSV encodes
miRNAs from their latency-associated transcripts (LATs), and these miRNAs
downregulate expression of cellular genes that induce apoptosis, thus allowing the latent
virus to remain in its host cell (57).
In our experiments, we were unable to describe a target of miR-VA and did not
observe a noticeable effect when we abrogated miR-VA function prior to infection.
However, in our experimental setting, we were attempting to test the function of miR-VA
under conditions where the lytic virus rapidly destroys its host cells.  Based on the
precedence of the other aforementioned viral miRNAs, it may be more appropriate to
study the function of miR-VA in a context where adenovirus replicates more slowly.
Reports of persistent adenovirus infection of adenoid and lymphoid tissues suggest that
lymphocytes in these tissues may harbor the virus (181). Evidence from the literature
further suggests that cultured human lymphocytes potentially provide a more appropriate
setting to examine a persistent state of adenovirus infection (87). Studies in such a quasi-
persistent setting may help us elucidate a function and/or cellular targets for miR-VA that
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is masked in our highly lytic infection setting.  It will also be beneficial to examine other
mammalian viruses for the presence of miRNAs.  To date, all the examples of viruses
producing miRNAs are DNA-based and are capable of entering a persistent or latent
stage of infection.  Seemingly good candidates for analysis would be other viruses that
have been demonstrated to show persistent or latent infections, such as parvoviruses, or
the hepatitis B and hepatitis D viruses.  For potential RNA viruses that produce miRNAs,
retroviruses would seemingly be the most obvious candidates, since they integrate into
the host genome, and their candidate miRNA genes could be expressed and processed
just like endogenous cellular miRNAs.
The role of RNA silencing in the response to mammalian viruses
The seemingly contradictory findings that some mammalian viruses encode RNA
silencing suppressors and other viruses encode miRNAs makes it difficult to interpret the
role of RNA silencing in mammalian virus infections.  Certainly, the answer is not as
straight forward as in plants and insects, which appear to use RNA silencing as a robust
anti-viral response.  In examining the data thus far, it would seem that the viral miRNA
demonstrations provide compelling evidence that viruses may utilize host silencing
responses to their own advantage.  The evidence for the some of the potential silencing
suppressors is clearly weakened by the fact that silencing suppression assays were
performed in plants and insects due to the limitations of studies in human cells.  It could
be that RNA silencing mechanisms, although present, do not contribute strongly to an
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anti-viral response. Mammals have evolved a complex and specific immune defense
against viruses, with the early innate response to dsRNA followed by a specific, cell
mediated response.  Perhaps the effects of an RNAi response is negligible in this context.
Additionally, the mammalian RNA silencing pathways are far less complex than those of
plants, and even insects, which use the silencing pathways for viral defense.  This again,
raises skepticism about the robustness of an RNA silencing anti-viral response in
mammals.  Despite all these caveats, it is still difficult to overlook some of the data
indicating that  RNA silencing plays an active role in immune defense.   The miRNA-
based regulation of PFV virus and its corresponding silencing suppressor are strong
indicators of an active role of RNA silencing in host defense.  Additionally, in the case of
HCV, a cellular miRNA appears to help define cellular tropism for the virus.  It is easy to
imagine that many cellular miRNAs are capable of targeting viral genes as well.
In actuality, it may be naïve to assume that RNA silencing either works “for” or
“against” the mammalian viruses.  Based on the current research, it appears that RNA
silencing pathways play different roles for different viruses.  The fact that all described
viral miRNAs are encoded by DNA viruses which are able to attain a persistent or latent
state of infection indicates that it is perhaps only these viruses which co-opt the use of the
RNA silencing pathway for their own viral fitness.  In contrast, RNA silencing machinery
may play a role in defense against non-latent viruses like vaccinia and influenza.
Selective action of an particular immune response against a virus are not unprecedented,
as some mammalian viruses are clearly more susceptible to cell-mediated immunity and
generate negligible antibody response.  In other instances of viral defense, neutralizing
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antibody responses play more prominent roles.  It is not trivial to think that viruses may
have similarly varying susceptibility to RNA silencing.
Even in our own experiments with adenovirus, we observe the seemingly
contradictory findings that adenovirus produces miRNAs, but also limits Dicer
expression during replication.  One interpretation of this data would be to that the virus is
interfering with RNA silencing pathways, and that the processing of miR-VA by Dicer
and subsequent incorporation into RISC is simply a consequence of the virus attempting
to saturate host silencing machinery.  This model implies an anti-viral activity of the
RNA silencing pathway, which adenovirus is non-specifically inhibiting by its expression
of large amounts of VA RNA.
Given the data from other persistent/latency-associated DNA viruses which
encode viral miRNAs, it seems that the production of miR-VA by adenovirus is not just a
coincidental artifact to VA RNA saturating the RNAi pathway.  Rather, it may be part of
the mechanism that helps adenovirus establish a persistent infection in appropriate
settings. Our kinetic analysis of miR-VA accumulation versus full length VA RNA
accumulation correlates well with the observed decrease in Dicer protein levels over the
course of infection (Figs. 3.5 & 4.3/4).  In another model, we would propose that VA
RNA is processed to miR-VA at very early times post infection.  We observe that the
accumulation of miRNA accumulation levels off quickly, possibly indicating saturation
of RNA processing components. Since miRNA-RISC complexes appear to be highly
stable, the miR-VA incorporated into RISC at these early times post-infection would
provide adenovirus with a pool of functional miRNA to target specific cellular genes that
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help the virus maintain a persistent infection (52).  Our kinetic analysis of miR-VA
versus full length VA RNA accumulation also indicates that when miR-VA accumulation
is leveling off (~ 12 h.p.i.), the production of VA RNA is greatly increased.  At these
times, very high levels of viral transcription are occurring, thus increasing the likelihood
that dsRNA intermediates are being produced.  The production of high levels of VA
RNA at this time allows the VA molecules to saturate PKR, thus preventing recognition
of viral dsRNA and the shutoff of host cell translation.  This model provides the rationale
for how the virus would quickly produce a miRNA promoting persistent infection before
Dicer levels are reduced transcriptionally, and also allows for the virus to maintain
regulation of PKR at appropriate times during infection.  This model additionally
supports the idea that the RNA silencing pathways can be both exploited by a virus to
perform a function that aids in viral persistence/fitness, and perform anti-viral regulatory
functions.
Summary
In summary, the data from this thesis presents evidence that human adenoviruses
encode miRNAs, produced from the VA RNA locus of the virus.  Additionally, we show
that virus infection leads to a decrease in expression of Dicer, a key component of
mammalian gene silencing pathways.  While the role of these interactions with RNA
silencing pathways remains to be fully elucidated, evidence from other viruses indicates
that these interactions may have important ramifications for viral fitness and immune
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evasion.  Finally, global studies of miRNA expression profiles during viral infections
indicate that viruses may produce specific miRNA signatures.  These studies implicate a
potential role of RNA silencing mechanisms as participants in the host response to animal
viruses.
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